{"transactions":[{"id":769594,"issuer":{"id":4463,"kind":"organization","name":"Aurinia Pharmaceuticals Inc.","symbol":"AUPH"},"owners":[{"id":45594,"kind":"person","name":"Hearne Michael S","position":1,"cik":"0001759910","reported_name":"Hearne Michael S","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Employee Stock Option (right to buy)","published_at":"2026-05-20T21:04:48.000Z","date":"2026-05-18","kind":"grant","planned":false,"acquired":true,"shares":70230,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"33% vest on the 1-year anniversary of the grant date, and the remaining 67% vest equally in monthly\ninstallments over the following 2 years."}],"balance_after":70230,"derivative":{"exercise_price":15.28,"expiration_date":"2036-05-18","underlying":"Common Stock","underlying_shares":70230},"source":{"system":"sec-edgar","filing":"0001759910-26-000004","document":"wk-form4_1779311085.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1600620/000175991026000004/wk-form4_1779311085.xml","form_type":"4"}},{"id":769593,"issuer":{"id":4463,"kind":"organization","name":"Aurinia Pharmaceuticals Inc.","symbol":"AUPH"},"owners":[{"id":45594,"kind":"person","name":"Hearne Michael S","position":1,"cik":"0001759910","reported_name":"Hearne Michael S","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Common Stock","published_at":"2026-05-20T21:04:48.000Z","date":"2026-05-18","kind":"grant","planned":false,"acquired":true,"shares":116144,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Each performance stock unit (\"PSU\") represents a contingent right to receive one common share of the Issuer. 46,820 PSUs vest in four tranches upon the Issuer's common shares achieving four progressively higher target prices, with respective one year retention periods per tranche achievement. 69,324 PSUs vest in two tranches at the three and five year anniversary date of grant if the Issuer's common shares achieve target prices that represent significant increases from the share price on date of grant before the respective vesting date."}],"balance_after":116144,"source":{"system":"sec-edgar","filing":"0001759910-26-000004","document":"wk-form4_1779311085.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1600620/000175991026000004/wk-form4_1779311085.xml","form_type":"4"}},{"id":2175366,"issuer":{"id":124310,"kind":"organization","name":"LA JOLLA PHARMACEUTICAL CO","symbol":"LJPC"},"owners":[{"id":45594,"kind":"person","name":"Hearne Michael S","position":1,"cik":"0001759910","reported_name":"Hearne Michael S","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Series C-1 (2) Convertible Preferred Stock","published_at":"2022-08-24T20:19:10.000Z","date":"2022-08-22","kind":"other","acquired":false,"shares":3519.315,"ownership":{"direct":false,"nature":"BY LP"},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F4","text":"Pursuant to the Merger Agreement, at the Effective Time, each share of Series C-12 Convertible Preferred Stock was converted into the right to receive an amount in cash equal to 1,724.04 times the Offer Price."},{"field":"price","element":"transactionPricePerShare","label":"F4","text":"Pursuant to the Merger Agreement, at the Effective Time, each share of Series C-12 Convertible Preferred Stock was converted into the right to receive an amount in cash equal to 1,724.04 times the Offer Price."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"Pursuant to the Merger Agreement, at the Effective Time, each share of Series C-12 Convertible Preferred Stock was converted into the right to receive an amount in cash equal to 1,724.04 times the Offer Price."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F4","text":"Pursuant to the Merger Agreement, at the Effective Time, each share of Series C-12 Convertible Preferred Stock was converted into the right to receive an amount in cash equal to 1,724.04 times the Offer Price."},{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F3","text":"The Shares are beneficially owned by Tang Capital Partners, LP (\"TCP\"). Tang Capital Management, LLC (\"TCM\") is the general partner of TCP. Michael Hearne is the Chief Financial Officer of La Jolla Pharmaceutical Company, as well as the Chief Financial Officer of TCM. Mr. Hearne has a pecuniary interest in the shares beneficially held by TCP."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"The Shares are beneficially owned by Tang Capital Partners, LP (\"TCP\"). Tang Capital Management, LLC (\"TCM\") is the general partner of TCP. Michael Hearne is the Chief Financial Officer of La Jolla Pharmaceutical Company, as well as the Chief Financial Officer of TCM. Mr. Hearne has a pecuniary interest in the shares beneficially held by TCP."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":6067439},"source":{"system":"sec-edgar","filing":"0000899243-22-029654","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":9,"url":"https://www.sec.gov/Archives/edgar/data/920465/000089924322029654/doc4.xml","form_type":"4"}},{"id":2175365,"issuer":{"id":124310,"kind":"organization","name":"LA JOLLA PHARMACEUTICAL CO","symbol":"LJPC"},"owners":[{"id":45594,"kind":"person","name":"Hearne Michael S","position":1,"cik":"0001759910","reported_name":"Hearne Michael S","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Employee Stock Option (Right to Buy)","published_at":"2022-08-24T20:19:10.000Z","date":"2022-08-22","kind":"disposition_to_issuer","acquired":false,"shares":236,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"This Form 4 reports securities disposed of pursuant to the terms of the Agreement and Plan of Merger (the \"Merger Agreement\"), dated as of July 10, 2022, by and among the Issuer, Innoviva, Inc., a Delaware corporation (\"Parent\"), and Innoviva Acquisition Sub, Inc., a Delaware corporation and a wholly owned subsidiary of the Parent (\"Purchaser\"), to which Purchaser completed a tender offer for shares of common stock of the Issuer, $0.0001 par value per share (each, a \"Share\"), and thereafter merged with and into the Issuer (the \"Merger\") effective as of August 22, 2022 (the \"Effective Time\")."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"(Continued from Footnote 1) Pursuant to the terms of the Merger Agreement, immediately prior to the Effective Time, each option to purchase Shares granted under an Issuer equity plan (each, an \"Issuer Stock Option\") that was outstanding and unexercised was cancelled and converted into the right to receive a cash payment equal to the excess, if any, of the Offer Price over the exercise price payable per Share with respect to such Issuer Stock Option."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"This Form 4 reports securities disposed of pursuant to the terms of the Agreement and Plan of Merger (the \"Merger Agreement\"), dated as of July 10, 2022, by and among the Issuer, Innoviva, Inc., a Delaware corporation (\"Parent\"), and Innoviva Acquisition Sub, Inc., a Delaware corporation and a wholly owned subsidiary of the Parent (\"Purchaser\"), to which Purchaser completed a tender offer for shares of common stock of the Issuer, $0.0001 par value per share (each, a \"Share\"), and thereafter merged with and into the Issuer (the \"Merger\") effective as of August 22, 2022 (the \"Effective Time\")."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"(Continued from Footnote 1) Pursuant to the terms of the Merger Agreement, immediately prior to the Effective Time, each option to purchase Shares granted under an Issuer equity plan (each, an \"Issuer Stock Option\") that was outstanding and unexercised was cancelled and converted into the right to receive a cash payment equal to the excess, if any, of the Offer Price over the exercise price payable per Share with respect to such Issuer Stock Option."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F1","text":"This Form 4 reports securities disposed of pursuant to the terms of the Agreement and Plan of Merger (the \"Merger Agreement\"), dated as of July 10, 2022, by and among the Issuer, Innoviva, Inc., a Delaware corporation (\"Parent\"), and Innoviva Acquisition Sub, Inc., a Delaware corporation and a wholly owned subsidiary of the Parent (\"Purchaser\"), to which Purchaser completed a tender offer for shares of common stock of the Issuer, $0.0001 par value per share (each, a \"Share\"), and thereafter merged with and into the Issuer (the \"Merger\") effective as of August 22, 2022 (the \"Effective Time\")."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F2","text":"(Continued from Footnote 1) Pursuant to the terms of the Merger Agreement, immediately prior to the Effective Time, each option to purchase Shares granted under an Issuer equity plan (each, an \"Issuer Stock Option\") that was outstanding and unexercised was cancelled and converted into the right to receive a cash payment equal to the excess, if any, of the Offer Price over the exercise price payable per Share with respect to such Issuer Stock Option."}],"balance_after":0,"derivative":{"exercise_price":3.19,"underlying":"Common Stock","underlying_shares":236},"source":{"system":"sec-edgar","filing":"0000899243-22-029654","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":8,"url":"https://www.sec.gov/Archives/edgar/data/920465/000089924322029654/doc4.xml","form_type":"4"}},{"id":2175364,"issuer":{"id":124310,"kind":"organization","name":"LA JOLLA PHARMACEUTICAL CO","symbol":"LJPC"},"owners":[{"id":45594,"kind":"person","name":"Hearne Michael S","position":1,"cik":"0001759910","reported_name":"Hearne Michael S","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Employee Stock Option (Right to Buy)","published_at":"2022-08-24T20:19:10.000Z","date":"2022-08-22","kind":"disposition_to_issuer","acquired":false,"shares":236,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"This Form 4 reports securities disposed of pursuant to the terms of the Agreement and Plan of Merger (the \"Merger Agreement\"), dated as of July 10, 2022, by and among the Issuer, Innoviva, Inc., a Delaware corporation (\"Parent\"), and Innoviva Acquisition Sub, Inc., a Delaware corporation and a wholly owned subsidiary of the Parent (\"Purchaser\"), to which Purchaser completed a tender offer for shares of common stock of the Issuer, $0.0001 par value per share (each, a \"Share\"), and thereafter merged with and into the Issuer (the \"Merger\") effective as of August 22, 2022 (the \"Effective Time\")."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"(Continued from Footnote 1) Pursuant to the terms of the Merger Agreement, immediately prior to the Effective Time, each option to purchase Shares granted under an Issuer equity plan (each, an \"Issuer Stock Option\") that was outstanding and unexercised was cancelled and converted into the right to receive a cash payment equal to the excess, if any, of the Offer Price over the exercise price payable per Share with respect to such Issuer Stock Option."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"This Form 4 reports securities disposed of pursuant to the terms of the Agreement and Plan of Merger (the \"Merger Agreement\"), dated as of July 10, 2022, by and among the Issuer, Innoviva, Inc., a Delaware corporation (\"Parent\"), and Innoviva Acquisition Sub, Inc., a Delaware corporation and a wholly owned subsidiary of the Parent (\"Purchaser\"), to which Purchaser completed a tender offer for shares of common stock of the Issuer, $0.0001 par value per share (each, a \"Share\"), and thereafter merged with and into the Issuer (the \"Merger\") effective as of August 22, 2022 (the \"Effective Time\")."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"(Continued from Footnote 1) Pursuant to the terms of the Merger Agreement, immediately prior to the Effective Time, each option to purchase Shares granted under an Issuer equity plan (each, an \"Issuer Stock Option\") that was outstanding and unexercised was cancelled and converted into the right to receive a cash payment equal to the excess, if any, of the Offer Price over the exercise price payable per Share with respect to such Issuer Stock Option."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F1","text":"This Form 4 reports securities disposed of pursuant to the terms of the Agreement and Plan of Merger (the \"Merger Agreement\"), dated as of July 10, 2022, by and among the Issuer, Innoviva, Inc., a Delaware corporation (\"Parent\"), and Innoviva Acquisition Sub, Inc., a Delaware corporation and a wholly owned subsidiary of the Parent (\"Purchaser\"), to which Purchaser completed a tender offer for shares of common stock of the Issuer, $0.0001 par value per share (each, a \"Share\"), and thereafter merged with and into the Issuer (the \"Merger\") effective as of August 22, 2022 (the \"Effective Time\")."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F2","text":"(Continued from Footnote 1) Pursuant to the terms of the Merger Agreement, immediately prior to the Effective Time, each option to purchase Shares granted under an Issuer equity plan (each, an \"Issuer Stock Option\") that was outstanding and unexercised was cancelled and converted into the right to receive a cash payment equal to the excess, if any, of the Offer Price over the exercise price payable per Share with respect to such Issuer Stock Option."}],"balance_after":0,"derivative":{"exercise_price":3.2,"underlying":"Common Stock","underlying_shares":236},"source":{"system":"sec-edgar","filing":"0000899243-22-029654","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":7,"url":"https://www.sec.gov/Archives/edgar/data/920465/000089924322029654/doc4.xml","form_type":"4"}},{"id":2175363,"issuer":{"id":124310,"kind":"organization","name":"LA JOLLA PHARMACEUTICAL CO","symbol":"LJPC"},"owners":[{"id":45594,"kind":"person","name":"Hearne Michael S","position":1,"cik":"0001759910","reported_name":"Hearne Michael S","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Employee Stock Option (Right to Buy)","published_at":"2022-08-24T20:19:10.000Z","date":"2022-08-22","kind":"disposition_to_issuer","acquired":false,"shares":185,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"This Form 4 reports securities disposed of pursuant to the terms of the Agreement and Plan of Merger (the \"Merger Agreement\"), dated as of July 10, 2022, by and among the Issuer, Innoviva, Inc., a Delaware corporation (\"Parent\"), and Innoviva Acquisition Sub, Inc., a Delaware corporation and a wholly owned subsidiary of the Parent (\"Purchaser\"), to which Purchaser completed a tender offer for shares of common stock of the Issuer, $0.0001 par value per share (each, a \"Share\"), and thereafter merged with and into the Issuer (the \"Merger\") effective as of August 22, 2022 (the \"Effective Time\")."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"(Continued from Footnote 1) Pursuant to the terms of the Merger Agreement, immediately prior to the Effective Time, each option to purchase Shares granted under an Issuer equity plan (each, an \"Issuer Stock Option\") that was outstanding and unexercised was cancelled and converted into the right to receive a cash payment equal to the excess, if any, of the Offer Price over the exercise price payable per Share with respect to such Issuer Stock Option."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"This Form 4 reports securities disposed of pursuant to the terms of the Agreement and Plan of Merger (the \"Merger Agreement\"), dated as of July 10, 2022, by and among the Issuer, Innoviva, Inc., a Delaware corporation (\"Parent\"), and Innoviva Acquisition Sub, Inc., a Delaware corporation and a wholly owned subsidiary of the Parent (\"Purchaser\"), to which Purchaser completed a tender offer for shares of common stock of the Issuer, $0.0001 par value per share (each, a \"Share\"), and thereafter merged with and into the Issuer (the \"Merger\") effective as of August 22, 2022 (the \"Effective Time\")."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"(Continued from Footnote 1) Pursuant to the terms of the Merger Agreement, immediately prior to the Effective Time, each option to purchase Shares granted under an Issuer equity plan (each, an \"Issuer Stock Option\") that was outstanding and unexercised was cancelled and converted into the right to receive a cash payment equal to the excess, if any, of the Offer Price over the exercise price payable per Share with respect to such Issuer Stock Option."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F1","text":"This Form 4 reports securities disposed of pursuant to the terms of the Agreement and Plan of Merger (the \"Merger Agreement\"), dated as of July 10, 2022, by and among the Issuer, Innoviva, Inc., a Delaware corporation (\"Parent\"), and Innoviva Acquisition Sub, Inc., a Delaware corporation and a wholly owned subsidiary of the Parent (\"Purchaser\"), to which Purchaser completed a tender offer for shares of common stock of the Issuer, $0.0001 par value per share (each, a \"Share\"), and thereafter merged with and into the Issuer (the \"Merger\") effective as of August 22, 2022 (the \"Effective Time\")."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F2","text":"(Continued from Footnote 1) Pursuant to the terms of the Merger Agreement, immediately prior to the Effective Time, each option to purchase Shares granted under an Issuer equity plan (each, an \"Issuer Stock Option\") that was outstanding and unexercised was cancelled and converted into the right to receive a cash payment equal to the excess, if any, of the Offer Price over the exercise price payable per Share with respect to such Issuer Stock Option."}],"balance_after":0,"derivative":{"exercise_price":4.08,"underlying":"Common Stock","underlying_shares":185},"source":{"system":"sec-edgar","filing":"0000899243-22-029654","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/920465/000089924322029654/doc4.xml","form_type":"4"}},{"id":2175362,"issuer":{"id":124310,"kind":"organization","name":"LA JOLLA PHARMACEUTICAL CO","symbol":"LJPC"},"owners":[{"id":45594,"kind":"person","name":"Hearne Michael S","position":1,"cik":"0001759910","reported_name":"Hearne Michael S","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Employee Stock Option (Right to Buy)","published_at":"2022-08-24T20:19:10.000Z","date":"2022-08-22","kind":"disposition_to_issuer","acquired":false,"shares":173,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"This Form 4 reports securities disposed of pursuant to the terms of the Agreement and Plan of Merger (the \"Merger Agreement\"), dated as of July 10, 2022, by and among the Issuer, Innoviva, Inc., a Delaware corporation (\"Parent\"), and Innoviva Acquisition Sub, Inc., a Delaware corporation and a wholly owned subsidiary of the Parent (\"Purchaser\"), to which Purchaser completed a tender offer for shares of common stock of the Issuer, $0.0001 par value per share (each, a \"Share\"), and thereafter merged with and into the Issuer (the \"Merger\") effective as of August 22, 2022 (the \"Effective Time\")."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"(Continued from Footnote 1) Pursuant to the terms of the Merger Agreement, immediately prior to the Effective Time, each option to purchase Shares granted under an Issuer equity plan (each, an \"Issuer Stock Option\") that was outstanding and unexercised was cancelled and converted into the right to receive a cash payment equal to the excess, if any, of the Offer Price over the exercise price payable per Share with respect to such Issuer Stock Option."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"This Form 4 reports securities disposed of pursuant to the terms of the Agreement and Plan of Merger (the \"Merger Agreement\"), dated as of July 10, 2022, by and among the Issuer, Innoviva, Inc., a Delaware corporation (\"Parent\"), and Innoviva Acquisition Sub, Inc., a Delaware corporation and a wholly owned subsidiary of the Parent (\"Purchaser\"), to which Purchaser completed a tender offer for shares of common stock of the Issuer, $0.0001 par value per share (each, a \"Share\"), and thereafter merged with and into the Issuer (the \"Merger\") effective as of August 22, 2022 (the \"Effective Time\")."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"(Continued from Footnote 1) Pursuant to the terms of the Merger Agreement, immediately prior to the Effective Time, each option to purchase Shares granted under an Issuer equity plan (each, an \"Issuer Stock Option\") that was outstanding and unexercised was cancelled and converted into the right to receive a cash payment equal to the excess, if any, of the Offer Price over the exercise price payable per Share with respect to such Issuer Stock Option."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F1","text":"This Form 4 reports securities disposed of pursuant to the terms of the Agreement and Plan of Merger (the \"Merger Agreement\"), dated as of July 10, 2022, by and among the Issuer, Innoviva, Inc., a Delaware corporation (\"Parent\"), and Innoviva Acquisition Sub, Inc., a Delaware corporation and a wholly owned subsidiary of the Parent (\"Purchaser\"), to which Purchaser completed a tender offer for shares of common stock of the Issuer, $0.0001 par value per share (each, a \"Share\"), and thereafter merged with and into the Issuer (the \"Merger\") effective as of August 22, 2022 (the \"Effective Time\")."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F2","text":"(Continued from Footnote 1) Pursuant to the terms of the Merger Agreement, immediately prior to the Effective Time, each option to purchase Shares granted under an Issuer equity plan (each, an \"Issuer Stock Option\") that was outstanding and unexercised was cancelled and converted into the right to receive a cash payment equal to the excess, if any, of the Offer Price over the exercise price payable per Share with respect to such Issuer Stock Option."}],"balance_after":0,"derivative":{"exercise_price":4.37,"underlying":"Common Stock","underlying_shares":173},"source":{"system":"sec-edgar","filing":"0000899243-22-029654","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/920465/000089924322029654/doc4.xml","form_type":"4"}},{"id":2175361,"issuer":{"id":124310,"kind":"organization","name":"LA JOLLA PHARMACEUTICAL CO","symbol":"LJPC"},"owners":[{"id":45594,"kind":"person","name":"Hearne Michael S","position":1,"cik":"0001759910","reported_name":"Hearne Michael S","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Employee Stock Option (Right to Buy)","published_at":"2022-08-24T20:19:10.000Z","date":"2022-08-22","kind":"disposition_to_issuer","acquired":false,"shares":177,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"This Form 4 reports securities disposed of pursuant to the terms of the Agreement and Plan of Merger (the \"Merger Agreement\"), dated as of July 10, 2022, by and among the Issuer, Innoviva, Inc., a Delaware corporation (\"Parent\"), and Innoviva Acquisition Sub, Inc., a Delaware corporation and a wholly owned subsidiary of the Parent (\"Purchaser\"), to which Purchaser completed a tender offer for shares of common stock of the Issuer, $0.0001 par value per share (each, a \"Share\"), and thereafter merged with and into the Issuer (the \"Merger\") effective as of August 22, 2022 (the \"Effective Time\")."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"(Continued from Footnote 1) Pursuant to the terms of the Merger Agreement, immediately prior to the Effective Time, each option to purchase Shares granted under an Issuer equity plan (each, an \"Issuer Stock Option\") that was outstanding and unexercised was cancelled and converted into the right to receive a cash payment equal to the excess, if any, of the Offer Price over the exercise price payable per Share with respect to such Issuer Stock Option."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"This Form 4 reports securities disposed of pursuant to the terms of the Agreement and Plan of Merger (the \"Merger Agreement\"), dated as of July 10, 2022, by and among the Issuer, Innoviva, Inc., a Delaware corporation (\"Parent\"), and Innoviva Acquisition Sub, Inc., a Delaware corporation and a wholly owned subsidiary of the Parent (\"Purchaser\"), to which Purchaser completed a tender offer for shares of common stock of the Issuer, $0.0001 par value per share (each, a \"Share\"), and thereafter merged with and into the Issuer (the \"Merger\") effective as of August 22, 2022 (the \"Effective Time\")."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"(Continued from Footnote 1) Pursuant to the terms of the Merger Agreement, immediately prior to the Effective Time, each option to purchase Shares granted under an Issuer equity plan (each, an \"Issuer Stock Option\") that was outstanding and unexercised was cancelled and converted into the right to receive a cash payment equal to the excess, if any, of the Offer Price over the exercise price payable per Share with respect to such Issuer Stock Option."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F1","text":"This Form 4 reports securities disposed of pursuant to the terms of the Agreement and Plan of Merger (the \"Merger Agreement\"), dated as of July 10, 2022, by and among the Issuer, Innoviva, Inc., a Delaware corporation (\"Parent\"), and Innoviva Acquisition Sub, Inc., a Delaware corporation and a wholly owned subsidiary of the Parent (\"Purchaser\"), to which Purchaser completed a tender offer for shares of common stock of the Issuer, $0.0001 par value per share (each, a \"Share\"), and thereafter merged with and into the Issuer (the \"Merger\") effective as of August 22, 2022 (the \"Effective Time\")."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F2","text":"(Continued from Footnote 1) Pursuant to the terms of the Merger Agreement, immediately prior to the Effective Time, each option to purchase Shares granted under an Issuer equity plan (each, an \"Issuer Stock Option\") that was outstanding and unexercised was cancelled and converted into the right to receive a cash payment equal to the excess, if any, of the Offer Price over the exercise price payable per Share with respect to such Issuer Stock Option."}],"balance_after":0,"derivative":{"exercise_price":4.27,"underlying":"Common Stock","underlying_shares":177},"source":{"system":"sec-edgar","filing":"0000899243-22-029654","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/920465/000089924322029654/doc4.xml","form_type":"4"}},{"id":2175360,"issuer":{"id":124310,"kind":"organization","name":"LA JOLLA PHARMACEUTICAL CO","symbol":"LJPC"},"owners":[{"id":45594,"kind":"person","name":"Hearne Michael S","position":1,"cik":"0001759910","reported_name":"Hearne Michael S","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Employee Stock Option (Right to Buy)","published_at":"2022-08-24T20:19:10.000Z","date":"2022-08-22","kind":"disposition_to_issuer","acquired":false,"shares":185,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"This Form 4 reports securities disposed of pursuant to the terms of the Agreement and Plan of Merger (the \"Merger Agreement\"), dated as of July 10, 2022, by and among the Issuer, Innoviva, Inc., a Delaware corporation (\"Parent\"), and Innoviva Acquisition Sub, Inc., a Delaware corporation and a wholly owned subsidiary of the Parent (\"Purchaser\"), to which Purchaser completed a tender offer for shares of common stock of the Issuer, $0.0001 par value per share (each, a \"Share\"), and thereafter merged with and into the Issuer (the \"Merger\") effective as of August 22, 2022 (the \"Effective Time\")."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"(Continued from Footnote 1) Pursuant to the terms of the Merger Agreement, immediately prior to the Effective Time, each option to purchase Shares granted under an Issuer equity plan (each, an \"Issuer Stock Option\") that was outstanding and unexercised was cancelled and converted into the right to receive a cash payment equal to the excess, if any, of the Offer Price over the exercise price payable per Share with respect to such Issuer Stock Option."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"This Form 4 reports securities disposed of pursuant to the terms of the Agreement and Plan of Merger (the \"Merger Agreement\"), dated as of July 10, 2022, by and among the Issuer, Innoviva, Inc., a Delaware corporation (\"Parent\"), and Innoviva Acquisition Sub, Inc., a Delaware corporation and a wholly owned subsidiary of the Parent (\"Purchaser\"), to which Purchaser completed a tender offer for shares of common stock of the Issuer, $0.0001 par value per share (each, a \"Share\"), and thereafter merged with and into the Issuer (the \"Merger\") effective as of August 22, 2022 (the \"Effective Time\")."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"(Continued from Footnote 1) Pursuant to the terms of the Merger Agreement, immediately prior to the Effective Time, each option to purchase Shares granted under an Issuer equity plan (each, an \"Issuer Stock Option\") that was outstanding and unexercised was cancelled and converted into the right to receive a cash payment equal to the excess, if any, of the Offer Price over the exercise price payable per Share with respect to such Issuer Stock Option."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F1","text":"This Form 4 reports securities disposed of pursuant to the terms of the Agreement and Plan of Merger (the \"Merger Agreement\"), dated as of July 10, 2022, by and among the Issuer, Innoviva, Inc., a Delaware corporation (\"Parent\"), and Innoviva Acquisition Sub, Inc., a Delaware corporation and a wholly owned subsidiary of the Parent (\"Purchaser\"), to which Purchaser completed a tender offer for shares of common stock of the Issuer, $0.0001 par value per share (each, a \"Share\"), and thereafter merged with and into the Issuer (the \"Merger\") effective as of August 22, 2022 (the \"Effective Time\")."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F2","text":"(Continued from Footnote 1) Pursuant to the terms of the Merger Agreement, immediately prior to the Effective Time, each option to purchase Shares granted under an Issuer equity plan (each, an \"Issuer Stock Option\") that was outstanding and unexercised was cancelled and converted into the right to receive a cash payment equal to the excess, if any, of the Offer Price over the exercise price payable per Share with respect to such Issuer Stock Option."}],"balance_after":0,"derivative":{"exercise_price":4.09,"underlying":"Common Stock","underlying_shares":185},"source":{"system":"sec-edgar","filing":"0000899243-22-029654","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/920465/000089924322029654/doc4.xml","form_type":"4"}},{"id":2175359,"issuer":{"id":124310,"kind":"organization","name":"LA JOLLA PHARMACEUTICAL CO","symbol":"LJPC"},"owners":[{"id":45594,"kind":"person","name":"Hearne Michael S","position":1,"cik":"0001759910","reported_name":"Hearne Michael S","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Employee Stock Option (Right to Buy)","published_at":"2022-08-24T20:19:10.000Z","date":"2022-08-22","kind":"disposition_to_issuer","acquired":false,"shares":169,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"This Form 4 reports securities disposed of pursuant to the terms of the Agreement and Plan of Merger (the \"Merger Agreement\"), dated as of July 10, 2022, by and among the Issuer, Innoviva, Inc., a Delaware corporation (\"Parent\"), and Innoviva Acquisition Sub, Inc., a Delaware corporation and a wholly owned subsidiary of the Parent (\"Purchaser\"), to which Purchaser completed a tender offer for shares of common stock of the Issuer, $0.0001 par value per share (each, a \"Share\"), and thereafter merged with and into the Issuer (the \"Merger\") effective as of August 22, 2022 (the \"Effective Time\")."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"(Continued from Footnote 1) Pursuant to the terms of the Merger Agreement, immediately prior to the Effective Time, each option to purchase Shares granted under an Issuer equity plan (each, an \"Issuer Stock Option\") that was outstanding and unexercised was cancelled and converted into the right to receive a cash payment equal to the excess, if any, of the Offer Price over the exercise price payable per Share with respect to such Issuer Stock Option."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"This Form 4 reports securities disposed of pursuant to the terms of the Agreement and Plan of Merger (the \"Merger Agreement\"), dated as of July 10, 2022, by and among the Issuer, Innoviva, Inc., a Delaware corporation (\"Parent\"), and Innoviva Acquisition Sub, Inc., a Delaware corporation and a wholly owned subsidiary of the Parent (\"Purchaser\"), to which Purchaser completed a tender offer for shares of common stock of the Issuer, $0.0001 par value per share (each, a \"Share\"), and thereafter merged with and into the Issuer (the \"Merger\") effective as of August 22, 2022 (the \"Effective Time\")."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"(Continued from Footnote 1) Pursuant to the terms of the Merger Agreement, immediately prior to the Effective Time, each option to purchase Shares granted under an Issuer equity plan (each, an \"Issuer Stock Option\") that was outstanding and unexercised was cancelled and converted into the right to receive a cash payment equal to the excess, if any, of the Offer Price over the exercise price payable per Share with respect to such Issuer Stock Option."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F1","text":"This Form 4 reports securities disposed of pursuant to the terms of the Agreement and Plan of Merger (the \"Merger Agreement\"), dated as of July 10, 2022, by and among the Issuer, Innoviva, Inc., a Delaware corporation (\"Parent\"), and Innoviva Acquisition Sub, Inc., a Delaware corporation and a wholly owned subsidiary of the Parent (\"Purchaser\"), to which Purchaser completed a tender offer for shares of common stock of the Issuer, $0.0001 par value per share (each, a \"Share\"), and thereafter merged with and into the Issuer (the \"Merger\") effective as of August 22, 2022 (the \"Effective Time\")."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F2","text":"(Continued from Footnote 1) Pursuant to the terms of the Merger Agreement, immediately prior to the Effective Time, each option to purchase Shares granted under an Issuer equity plan (each, an \"Issuer Stock Option\") that was outstanding and unexercised was cancelled and converted into the right to receive a cash payment equal to the excess, if any, of the Offer Price over the exercise price payable per Share with respect to such Issuer Stock Option."}],"balance_after":0,"derivative":{"exercise_price":4.46,"underlying":"Common Stock","underlying_shares":169},"source":{"system":"sec-edgar","filing":"0000899243-22-029654","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/920465/000089924322029654/doc4.xml","form_type":"4"}},{"id":2175358,"issuer":{"id":124310,"kind":"organization","name":"LA JOLLA PHARMACEUTICAL CO","symbol":"LJPC"},"owners":[{"id":45594,"kind":"person","name":"Hearne Michael S","position":1,"cik":"0001759910","reported_name":"Hearne Michael S","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Employee Stock Option (Right to Buy)","published_at":"2022-08-24T20:19:10.000Z","date":"2022-08-22","kind":"disposition_to_issuer","acquired":false,"shares":1675,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"This Form 4 reports securities disposed of pursuant to the terms of the Agreement and Plan of Merger (the \"Merger Agreement\"), dated as of July 10, 2022, by and among the Issuer, Innoviva, Inc., a Delaware corporation (\"Parent\"), and Innoviva Acquisition Sub, Inc., a Delaware corporation and a wholly owned subsidiary of the Parent (\"Purchaser\"), to which Purchaser completed a tender offer for shares of common stock of the Issuer, $0.0001 par value per share (each, a \"Share\"), and thereafter merged with and into the Issuer (the \"Merger\") effective as of August 22, 2022 (the \"Effective Time\")."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"(Continued from Footnote 1) Pursuant to the terms of the Merger Agreement, immediately prior to the Effective Time, each option to purchase Shares granted under an Issuer equity plan (each, an \"Issuer Stock Option\") that was outstanding and unexercised was cancelled and converted into the right to receive a cash payment equal to the excess, if any, of the Offer Price over the exercise price payable per Share with respect to such Issuer Stock Option."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"This Form 4 reports securities disposed of pursuant to the terms of the Agreement and Plan of Merger (the \"Merger Agreement\"), dated as of July 10, 2022, by and among the Issuer, Innoviva, Inc., a Delaware corporation (\"Parent\"), and Innoviva Acquisition Sub, Inc., a Delaware corporation and a wholly owned subsidiary of the Parent (\"Purchaser\"), to which Purchaser completed a tender offer for shares of common stock of the Issuer, $0.0001 par value per share (each, a \"Share\"), and thereafter merged with and into the Issuer (the \"Merger\") effective as of August 22, 2022 (the \"Effective Time\")."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"(Continued from Footnote 1) Pursuant to the terms of the Merger Agreement, immediately prior to the Effective Time, each option to purchase Shares granted under an Issuer equity plan (each, an \"Issuer Stock Option\") that was outstanding and unexercised was cancelled and converted into the right to receive a cash payment equal to the excess, if any, of the Offer Price over the exercise price payable per Share with respect to such Issuer Stock Option."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F1","text":"This Form 4 reports securities disposed of pursuant to the terms of the Agreement and Plan of Merger (the \"Merger Agreement\"), dated as of July 10, 2022, by and among the Issuer, Innoviva, Inc., a Delaware corporation (\"Parent\"), and Innoviva Acquisition Sub, Inc., a Delaware corporation and a wholly owned subsidiary of the Parent (\"Purchaser\"), to which Purchaser completed a tender offer for shares of common stock of the Issuer, $0.0001 par value per share (each, a \"Share\"), and thereafter merged with and into the Issuer (the \"Merger\") effective as of August 22, 2022 (the \"Effective Time\")."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F2","text":"(Continued from Footnote 1) Pursuant to the terms of the Merger Agreement, immediately prior to the Effective Time, each option to purchase Shares granted under an Issuer equity plan (each, an \"Issuer Stock Option\") that was outstanding and unexercised was cancelled and converted into the right to receive a cash payment equal to the excess, if any, of the Offer Price over the exercise price payable per Share with respect to such Issuer Stock Option."}],"balance_after":0,"derivative":{"exercise_price":4.63,"underlying":"Common Stock","underlying_shares":1675},"source":{"system":"sec-edgar","filing":"0000899243-22-029654","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/920465/000089924322029654/doc4.xml","form_type":"4"}},{"id":2175333,"issuer":{"id":124310,"kind":"organization","name":"LA JOLLA PHARMACEUTICAL CO","symbol":"LJPC"},"owners":[{"id":45594,"kind":"person","name":"Hearne Michael S","position":1,"cik":"0001759910","reported_name":"Hearne Michael S","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Employee Stock Option (Right to Buy)","published_at":"2022-08-24T20:17:34.000Z","date":"2022-08-22","kind":"disposition_to_issuer","acquired":false,"shares":148,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F3","text":"Pursuant to the terms of the Merger Agreement, immediately prior to the Effective Time, each option to purchase Shares granted under an Issuer equity plan (each, an \"Issuer Stock Option\") that was outstanding and unexercised was cancelled and converted into the right to receive a cash payment equal to the excess, if any, of the Offer Price over the exercise price payable per Share with respect to such Issuer Stock Option."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"Pursuant to the terms of the Merger Agreement, immediately prior to the Effective Time, each option to purchase Shares granted under an Issuer equity plan (each, an \"Issuer Stock Option\") that was outstanding and unexercised was cancelled and converted into the right to receive a cash payment equal to the excess, if any, of the Offer Price over the exercise price payable per Share with respect to such Issuer Stock Option."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F3","text":"Pursuant to the terms of the Merger Agreement, immediately prior to the Effective Time, each option to purchase Shares granted under an Issuer equity plan (each, an \"Issuer Stock Option\") that was outstanding and unexercised was cancelled and converted into the right to receive a cash payment equal to the excess, if any, of the Offer Price over the exercise price payable per Share with respect to such Issuer Stock Option."}],"balance_after":0,"derivative":{"exercise_price":4.92,"underlying":"Common Stock","underlying_shares":148},"source":{"system":"sec-edgar","filing":"0000899243-22-029649","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":32,"url":"https://www.sec.gov/Archives/edgar/data/920465/000089924322029649/doc4.xml","form_type":"4"}},{"id":2175332,"issuer":{"id":124310,"kind":"organization","name":"LA JOLLA PHARMACEUTICAL CO","symbol":"LJPC"},"owners":[{"id":45594,"kind":"person","name":"Hearne Michael S","position":1,"cik":"0001759910","reported_name":"Hearne Michael S","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Employee Stock Option (Right to Buy)","published_at":"2022-08-24T20:17:34.000Z","date":"2022-08-22","kind":"disposition_to_issuer","acquired":false,"shares":78552,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F3","text":"Pursuant to the terms of the Merger Agreement, immediately prior to the Effective Time, each option to purchase Shares granted under an Issuer equity plan (each, an \"Issuer Stock Option\") that was outstanding and unexercised was cancelled and converted into the right to receive a cash payment equal to the excess, if any, of the Offer Price over the exercise price payable per Share with respect to such Issuer Stock Option."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"Pursuant to the terms of the Merger Agreement, immediately prior to the Effective Time, each option to purchase Shares granted under an Issuer equity plan (each, an \"Issuer Stock Option\") that was outstanding and unexercised was cancelled and converted into the right to receive a cash payment equal to the excess, if any, of the Offer Price over the exercise price payable per Share with respect to such Issuer Stock Option."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F3","text":"Pursuant to the terms of the Merger Agreement, immediately prior to the Effective Time, each option to purchase Shares granted under an Issuer equity plan (each, an \"Issuer Stock Option\") that was outstanding and unexercised was cancelled and converted into the right to receive a cash payment equal to the excess, if any, of the Offer Price over the exercise price payable per Share with respect to such Issuer Stock Option."}],"balance_after":0,"derivative":{"exercise_price":4.81,"underlying":"Common Stock","underlying_shares":78552},"source":{"system":"sec-edgar","filing":"0000899243-22-029649","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":31,"url":"https://www.sec.gov/Archives/edgar/data/920465/000089924322029649/doc4.xml","form_type":"4"}},{"id":2175331,"issuer":{"id":124310,"kind":"organization","name":"LA JOLLA PHARMACEUTICAL CO","symbol":"LJPC"},"owners":[{"id":45594,"kind":"person","name":"Hearne Michael S","position":1,"cik":"0001759910","reported_name":"Hearne Michael S","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Employee Stock Option (Right to Buy)","published_at":"2022-08-24T20:17:34.000Z","date":"2022-08-22","kind":"disposition_to_issuer","acquired":false,"shares":157,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F3","text":"Pursuant to the terms of the Merger Agreement, immediately prior to the Effective Time, each option to purchase Shares granted under an Issuer equity plan (each, an \"Issuer Stock Option\") that was outstanding and unexercised was cancelled and converted into the right to receive a cash payment equal to the excess, if any, of the Offer Price over the exercise price payable per Share with respect to such Issuer Stock Option."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"Pursuant to the terms of the Merger Agreement, immediately prior to the Effective Time, each option to purchase Shares granted under an Issuer equity plan (each, an \"Issuer Stock Option\") that was outstanding and unexercised was cancelled and converted into the right to receive a cash payment equal to the excess, if any, of the Offer Price over the exercise price payable per Share with respect to such Issuer Stock Option."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F3","text":"Pursuant to the terms of the Merger Agreement, immediately prior to the Effective Time, each option to purchase Shares granted under an Issuer equity plan (each, an \"Issuer Stock Option\") that was outstanding and unexercised was cancelled and converted into the right to receive a cash payment equal to the excess, if any, of the Offer Price over the exercise price payable per Share with respect to such Issuer Stock Option."}],"balance_after":0,"derivative":{"exercise_price":4.61,"underlying":"Common Stock","underlying_shares":157},"source":{"system":"sec-edgar","filing":"0000899243-22-029649","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":30,"url":"https://www.sec.gov/Archives/edgar/data/920465/000089924322029649/doc4.xml","form_type":"4"}},{"id":2175330,"issuer":{"id":124310,"kind":"organization","name":"LA JOLLA PHARMACEUTICAL CO","symbol":"LJPC"},"owners":[{"id":45594,"kind":"person","name":"Hearne Michael S","position":1,"cik":"0001759910","reported_name":"Hearne Michael S","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Employee Stock Option (Right to Buy)","published_at":"2022-08-24T20:17:34.000Z","date":"2022-08-22","kind":"disposition_to_issuer","acquired":false,"shares":173,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F3","text":"Pursuant to the terms of the Merger Agreement, immediately prior to the Effective Time, each option to purchase Shares granted under an Issuer equity plan (each, an \"Issuer Stock Option\") that was outstanding and unexercised was cancelled and converted into the right to receive a cash payment equal to the excess, if any, of the Offer Price over the exercise price payable per Share with respect to such Issuer Stock Option."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"Pursuant to the terms of the Merger Agreement, immediately prior to the Effective Time, each option to purchase Shares granted under an Issuer equity plan (each, an \"Issuer Stock Option\") that was outstanding and unexercised was cancelled and converted into the right to receive a cash payment equal to the excess, if any, of the Offer Price over the exercise price payable per Share with respect to such Issuer Stock Option."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F3","text":"Pursuant to the terms of the Merger Agreement, immediately prior to the Effective Time, each option to purchase Shares granted under an Issuer equity plan (each, an \"Issuer Stock Option\") that was outstanding and unexercised was cancelled and converted into the right to receive a cash payment equal to the excess, if any, of the Offer Price over the exercise price payable per Share with respect to such Issuer Stock Option."}],"balance_after":0,"derivative":{"exercise_price":4.21,"underlying":"Common Stock","underlying_shares":173},"source":{"system":"sec-edgar","filing":"0000899243-22-029649","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":29,"url":"https://www.sec.gov/Archives/edgar/data/920465/000089924322029649/doc4.xml","form_type":"4"}},{"id":2175329,"issuer":{"id":124310,"kind":"organization","name":"LA JOLLA PHARMACEUTICAL CO","symbol":"LJPC"},"owners":[{"id":45594,"kind":"person","name":"Hearne Michael S","position":1,"cik":"0001759910","reported_name":"Hearne Michael S","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Employee Stock Option (Right to Buy)","published_at":"2022-08-24T20:17:34.000Z","date":"2022-08-22","kind":"disposition_to_issuer","acquired":false,"shares":186,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F3","text":"Pursuant to the terms of the Merger Agreement, immediately prior to the Effective Time, each option to purchase Shares granted under an Issuer equity plan (each, an \"Issuer Stock Option\") that was outstanding and unexercised was cancelled and converted into the right to receive a cash payment equal to the excess, if any, of the Offer Price over the exercise price payable per Share with respect to such Issuer Stock Option."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"Pursuant to the terms of the Merger Agreement, immediately prior to the Effective Time, each option to purchase Shares granted under an Issuer equity plan (each, an \"Issuer Stock Option\") that was outstanding and unexercised was cancelled and converted into the right to receive a cash payment equal to the excess, if any, of the Offer Price over the exercise price payable per Share with respect to such Issuer Stock Option."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F3","text":"Pursuant to the terms of the Merger Agreement, immediately prior to the Effective Time, each option to purchase Shares granted under an Issuer equity plan (each, an \"Issuer Stock Option\") that was outstanding and unexercised was cancelled and converted into the right to receive a cash payment equal to the excess, if any, of the Offer Price over the exercise price payable per Share with respect to such Issuer Stock Option."}],"balance_after":0,"derivative":{"exercise_price":3.9,"underlying":"Common Stock","underlying_shares":186},"source":{"system":"sec-edgar","filing":"0000899243-22-029649","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":28,"url":"https://www.sec.gov/Archives/edgar/data/920465/000089924322029649/doc4.xml","form_type":"4"}},{"id":2175328,"issuer":{"id":124310,"kind":"organization","name":"LA JOLLA PHARMACEUTICAL CO","symbol":"LJPC"},"owners":[{"id":45594,"kind":"person","name":"Hearne Michael S","position":1,"cik":"0001759910","reported_name":"Hearne Michael S","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Employee Stock Option (Right to Buy)","published_at":"2022-08-24T20:17:34.000Z","date":"2022-08-22","kind":"disposition_to_issuer","acquired":false,"shares":558,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F3","text":"Pursuant to the terms of the Merger Agreement, immediately prior to the Effective Time, each option to purchase Shares granted under an Issuer equity plan (each, an \"Issuer Stock Option\") that was outstanding and unexercised was cancelled and converted into the right to receive a cash payment equal to the excess, if any, of the Offer Price over the exercise price payable per Share with respect to such Issuer Stock Option."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"Pursuant to the terms of the Merger Agreement, immediately prior to the Effective Time, each option to purchase Shares granted under an Issuer equity plan (each, an \"Issuer Stock Option\") that was outstanding and unexercised was cancelled and converted into the right to receive a cash payment equal to the excess, if any, of the Offer Price over the exercise price payable per Share with respect to such Issuer Stock Option."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F3","text":"Pursuant to the terms of the Merger Agreement, immediately prior to the Effective Time, each option to purchase Shares granted under an Issuer equity plan (each, an \"Issuer Stock Option\") that was outstanding and unexercised was cancelled and converted into the right to receive a cash payment equal to the excess, if any, of the Offer Price over the exercise price payable per Share with respect to such Issuer Stock Option."}],"balance_after":0,"derivative":{"exercise_price":4.01,"underlying":"Common Stock","underlying_shares":558},"source":{"system":"sec-edgar","filing":"0000899243-22-029649","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":27,"url":"https://www.sec.gov/Archives/edgar/data/920465/000089924322029649/doc4.xml","form_type":"4"}},{"id":2175327,"issuer":{"id":124310,"kind":"organization","name":"LA JOLLA PHARMACEUTICAL CO","symbol":"LJPC"},"owners":[{"id":45594,"kind":"person","name":"Hearne Michael S","position":1,"cik":"0001759910","reported_name":"Hearne Michael S","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Employee Stock Option (Right to Buy)","published_at":"2022-08-24T20:17:34.000Z","date":"2022-08-22","kind":"disposition_to_issuer","acquired":false,"shares":181,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F3","text":"Pursuant to the terms of the Merger Agreement, immediately prior to the Effective Time, each option to purchase Shares granted under an Issuer equity plan (each, an \"Issuer Stock Option\") that was outstanding and unexercised was cancelled and converted into the right to receive a cash payment equal to the excess, if any, of the Offer Price over the exercise price payable per Share with respect to such Issuer Stock Option."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"Pursuant to the terms of the Merger Agreement, immediately prior to the Effective Time, each option to purchase Shares granted under an Issuer equity plan (each, an \"Issuer Stock Option\") that was outstanding and unexercised was cancelled and converted into the right to receive a cash payment equal to the excess, if any, of the Offer Price over the exercise price payable per Share with respect to such Issuer Stock Option."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F3","text":"Pursuant to the terms of the Merger Agreement, immediately prior to the Effective Time, each option to purchase Shares granted under an Issuer equity plan (each, an \"Issuer Stock Option\") that was outstanding and unexercised was cancelled and converted into the right to receive a cash payment equal to the excess, if any, of the Offer Price over the exercise price payable per Share with respect to such Issuer Stock Option."}],"balance_after":0,"derivative":{"exercise_price":4.02,"underlying":"Common Stock","underlying_shares":181},"source":{"system":"sec-edgar","filing":"0000899243-22-029649","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":26,"url":"https://www.sec.gov/Archives/edgar/data/920465/000089924322029649/doc4.xml","form_type":"4"}},{"id":2175326,"issuer":{"id":124310,"kind":"organization","name":"LA JOLLA PHARMACEUTICAL CO","symbol":"LJPC"},"owners":[{"id":45594,"kind":"person","name":"Hearne Michael S","position":1,"cik":"0001759910","reported_name":"Hearne Michael S","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Employee Stock Option (Right to Buy)","published_at":"2022-08-24T20:17:34.000Z","date":"2022-08-22","kind":"disposition_to_issuer","acquired":false,"shares":373,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F3","text":"Pursuant to the terms of the Merger Agreement, immediately prior to the Effective Time, each option to purchase Shares granted under an Issuer equity plan (each, an \"Issuer Stock Option\") that was outstanding and unexercised was cancelled and converted into the right to receive a cash payment equal to the excess, if any, of the Offer Price over the exercise price payable per Share with respect to such Issuer Stock Option."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"Pursuant to the terms of the Merger Agreement, immediately prior to the Effective Time, each option to purchase Shares granted under an Issuer equity plan (each, an \"Issuer Stock Option\") that was outstanding and unexercised was cancelled and converted into the right to receive a cash payment equal to the excess, if any, of the Offer Price over the exercise price payable per Share with respect to such Issuer Stock Option."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F3","text":"Pursuant to the terms of the Merger Agreement, immediately prior to the Effective Time, each option to purchase Shares granted under an Issuer equity plan (each, an \"Issuer Stock Option\") that was outstanding and unexercised was cancelled and converted into the right to receive a cash payment equal to the excess, if any, of the Offer Price over the exercise price payable per Share with respect to such Issuer Stock Option."}],"balance_after":0,"derivative":{"exercise_price":3.96,"underlying":"Common Stock","underlying_shares":373},"source":{"system":"sec-edgar","filing":"0000899243-22-029649","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":25,"url":"https://www.sec.gov/Archives/edgar/data/920465/000089924322029649/doc4.xml","form_type":"4"}},{"id":2175325,"issuer":{"id":124310,"kind":"organization","name":"LA JOLLA PHARMACEUTICAL CO","symbol":"LJPC"},"owners":[{"id":45594,"kind":"person","name":"Hearne Michael S","position":1,"cik":"0001759910","reported_name":"Hearne Michael S","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Employee Stock Option (Right to Buy)","published_at":"2022-08-24T20:17:34.000Z","date":"2022-08-22","kind":"disposition_to_issuer","acquired":false,"shares":728,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F3","text":"Pursuant to the terms of the Merger Agreement, immediately prior to the Effective Time, each option to purchase Shares granted under an Issuer equity plan (each, an \"Issuer Stock Option\") that was outstanding and unexercised was cancelled and converted into the right to receive a cash payment equal to the excess, if any, of the Offer Price over the exercise price payable per Share with respect to such Issuer Stock Option."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"Pursuant to the terms of the Merger Agreement, immediately prior to the Effective Time, each option to purchase Shares granted under an Issuer equity plan (each, an \"Issuer Stock Option\") that was outstanding and unexercised was cancelled and converted into the right to receive a cash payment equal to the excess, if any, of the Offer Price over the exercise price payable per Share with respect to such Issuer Stock Option."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F3","text":"Pursuant to the terms of the Merger Agreement, immediately prior to the Effective Time, each option to purchase Shares granted under an Issuer equity plan (each, an \"Issuer Stock Option\") that was outstanding and unexercised was cancelled and converted into the right to receive a cash payment equal to the excess, if any, of the Offer Price over the exercise price payable per Share with respect to such Issuer Stock Option."}],"balance_after":0,"derivative":{"exercise_price":3.99,"underlying":"Common Stock","underlying_shares":728},"source":{"system":"sec-edgar","filing":"0000899243-22-029649","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":24,"url":"https://www.sec.gov/Archives/edgar/data/920465/000089924322029649/doc4.xml","form_type":"4"}},{"id":2175324,"issuer":{"id":124310,"kind":"organization","name":"LA JOLLA PHARMACEUTICAL CO","symbol":"LJPC"},"owners":[{"id":45594,"kind":"person","name":"Hearne Michael S","position":1,"cik":"0001759910","reported_name":"Hearne Michael S","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Employee Stock Option (Right to Buy)","published_at":"2022-08-24T20:17:34.000Z","date":"2022-08-22","kind":"disposition_to_issuer","acquired":false,"shares":201,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F3","text":"Pursuant to the terms of the Merger Agreement, immediately prior to the Effective Time, each option to purchase Shares granted under an Issuer equity plan (each, an \"Issuer Stock Option\") that was outstanding and unexercised was cancelled and converted into the right to receive a cash payment equal to the excess, if any, of the Offer Price over the exercise price payable per Share with respect to such Issuer Stock Option."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"Pursuant to the terms of the Merger Agreement, immediately prior to the Effective Time, each option to purchase Shares granted under an Issuer equity plan (each, an \"Issuer Stock Option\") that was outstanding and unexercised was cancelled and converted into the right to receive a cash payment equal to the excess, if any, of the Offer Price over the exercise price payable per Share with respect to such Issuer Stock Option."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F3","text":"Pursuant to the terms of the Merger Agreement, immediately prior to the Effective Time, each option to purchase Shares granted under an Issuer equity plan (each, an \"Issuer Stock Option\") that was outstanding and unexercised was cancelled and converted into the right to receive a cash payment equal to the excess, if any, of the Offer Price over the exercise price payable per Share with respect to such Issuer Stock Option."}],"balance_after":0,"derivative":{"exercise_price":3.61,"underlying":"Common Stock","underlying_shares":201},"source":{"system":"sec-edgar","filing":"0000899243-22-029649","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":23,"url":"https://www.sec.gov/Archives/edgar/data/920465/000089924322029649/doc4.xml","form_type":"4"}},{"id":2175323,"issuer":{"id":124310,"kind":"organization","name":"LA JOLLA PHARMACEUTICAL CO","symbol":"LJPC"},"owners":[{"id":45594,"kind":"person","name":"Hearne Michael S","position":1,"cik":"0001759910","reported_name":"Hearne Michael S","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Employee Stock Option (Right to Buy)","published_at":"2022-08-24T20:17:34.000Z","date":"2022-08-22","kind":"disposition_to_issuer","acquired":false,"shares":170,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F3","text":"Pursuant to the terms of the Merger Agreement, immediately prior to the Effective Time, each option to purchase Shares granted under an Issuer equity plan (each, an \"Issuer Stock Option\") that was outstanding and unexercised was cancelled and converted into the right to receive a cash payment equal to the excess, if any, of the Offer Price over the exercise price payable per Share with respect to such Issuer Stock Option."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"Pursuant to the terms of the Merger Agreement, immediately prior to the Effective Time, each option to purchase Shares granted under an Issuer equity plan (each, an \"Issuer Stock Option\") that was outstanding and unexercised was cancelled and converted into the right to receive a cash payment equal to the excess, if any, of the Offer Price over the exercise price payable per Share with respect to such Issuer Stock Option."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F3","text":"Pursuant to the terms of the Merger Agreement, immediately prior to the Effective Time, each option to purchase Shares granted under an Issuer equity plan (each, an \"Issuer Stock Option\") that was outstanding and unexercised was cancelled and converted into the right to receive a cash payment equal to the excess, if any, of the Offer Price over the exercise price payable per Share with respect to such Issuer Stock Option."}],"balance_after":0,"derivative":{"exercise_price":4.28,"underlying":"Common Stock","underlying_shares":170},"source":{"system":"sec-edgar","filing":"0000899243-22-029649","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":22,"url":"https://www.sec.gov/Archives/edgar/data/920465/000089924322029649/doc4.xml","form_type":"4"}},{"id":2175322,"issuer":{"id":124310,"kind":"organization","name":"LA JOLLA PHARMACEUTICAL CO","symbol":"LJPC"},"owners":[{"id":45594,"kind":"person","name":"Hearne Michael S","position":1,"cik":"0001759910","reported_name":"Hearne Michael S","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Employee Stock Option (Right to Buy)","published_at":"2022-08-24T20:17:34.000Z","date":"2022-08-22","kind":"disposition_to_issuer","acquired":false,"shares":148,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F3","text":"Pursuant to the terms of the Merger Agreement, immediately prior to the Effective Time, each option to purchase Shares granted under an Issuer equity plan (each, an \"Issuer Stock Option\") that was outstanding and unexercised was cancelled and converted into the right to receive a cash payment equal to the excess, if any, of the Offer Price over the exercise price payable per Share with respect to such Issuer Stock Option."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"Pursuant to the terms of the Merger Agreement, immediately prior to the Effective Time, each option to purchase Shares granted under an Issuer equity plan (each, an \"Issuer Stock Option\") that was outstanding and unexercised was cancelled and converted into the right to receive a cash payment equal to the excess, if any, of the Offer Price over the exercise price payable per Share with respect to such Issuer Stock Option."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F3","text":"Pursuant to the terms of the Merger Agreement, immediately prior to the Effective Time, each option to purchase Shares granted under an Issuer equity plan (each, an \"Issuer Stock Option\") that was outstanding and unexercised was cancelled and converted into the right to receive a cash payment equal to the excess, if any, of the Offer Price over the exercise price payable per Share with respect to such Issuer Stock Option."}],"balance_after":0,"derivative":{"exercise_price":4.9,"underlying":"Common Stock","underlying_shares":148},"source":{"system":"sec-edgar","filing":"0000899243-22-029649","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":21,"url":"https://www.sec.gov/Archives/edgar/data/920465/000089924322029649/doc4.xml","form_type":"4"}},{"id":2175321,"issuer":{"id":124310,"kind":"organization","name":"LA JOLLA PHARMACEUTICAL CO","symbol":"LJPC"},"owners":[{"id":45594,"kind":"person","name":"Hearne Michael S","position":1,"cik":"0001759910","reported_name":"Hearne Michael S","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Employee Stock Option (Right to Buy)","published_at":"2022-08-24T20:17:34.000Z","date":"2022-08-22","kind":"disposition_to_issuer","acquired":false,"shares":169,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F3","text":"Pursuant to the terms of the Merger Agreement, immediately prior to the Effective Time, each option to purchase Shares granted under an Issuer equity plan (each, an \"Issuer Stock Option\") that was outstanding and unexercised was cancelled and converted into the right to receive a cash payment equal to the excess, if any, of the Offer Price over the exercise price payable per Share with respect to such Issuer Stock Option."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"Pursuant to the terms of the Merger Agreement, immediately prior to the Effective Time, each option to purchase Shares granted under an Issuer equity plan (each, an \"Issuer Stock Option\") that was outstanding and unexercised was cancelled and converted into the right to receive a cash payment equal to the excess, if any, of the Offer Price over the exercise price payable per Share with respect to such Issuer Stock Option."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F3","text":"Pursuant to the terms of the Merger Agreement, immediately prior to the Effective Time, each option to purchase Shares granted under an Issuer equity plan (each, an \"Issuer Stock Option\") that was outstanding and unexercised was cancelled and converted into the right to receive a cash payment equal to the excess, if any, of the Offer Price over the exercise price payable per Share with respect to such Issuer Stock Option."}],"balance_after":0,"derivative":{"exercise_price":4.3,"underlying":"Common Stock","underlying_shares":169},"source":{"system":"sec-edgar","filing":"0000899243-22-029649","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":20,"url":"https://www.sec.gov/Archives/edgar/data/920465/000089924322029649/doc4.xml","form_type":"4"}},{"id":2175320,"issuer":{"id":124310,"kind":"organization","name":"LA JOLLA PHARMACEUTICAL CO","symbol":"LJPC"},"owners":[{"id":45594,"kind":"person","name":"Hearne Michael S","position":1,"cik":"0001759910","reported_name":"Hearne Michael S","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Employee Stock Option (Right to Buy)","published_at":"2022-08-24T20:17:34.000Z","date":"2022-08-22","kind":"disposition_to_issuer","acquired":false,"shares":386,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F3","text":"Pursuant to the terms of the Merger Agreement, immediately prior to the Effective Time, each option to purchase Shares granted under an Issuer equity plan (each, an \"Issuer Stock Option\") that was outstanding and unexercised was cancelled and converted into the right to receive a cash payment equal to the excess, if any, of the Offer Price over the exercise price payable per Share with respect to such Issuer Stock Option."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"Pursuant to the terms of the Merger Agreement, immediately prior to the Effective Time, each option to purchase Shares granted under an Issuer equity plan (each, an \"Issuer Stock Option\") that was outstanding and unexercised was cancelled and converted into the right to receive a cash payment equal to the excess, if any, of the Offer Price over the exercise price payable per Share with respect to such Issuer Stock Option."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F3","text":"Pursuant to the terms of the Merger Agreement, immediately prior to the Effective Time, each option to purchase Shares granted under an Issuer equity plan (each, an \"Issuer Stock Option\") that was outstanding and unexercised was cancelled and converted into the right to receive a cash payment equal to the excess, if any, of the Offer Price over the exercise price payable per Share with respect to such Issuer Stock Option."}],"balance_after":0,"derivative":{"exercise_price":3.76,"underlying":"Common Stock","underlying_shares":386},"source":{"system":"sec-edgar","filing":"0000899243-22-029649","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":19,"url":"https://www.sec.gov/Archives/edgar/data/920465/000089924322029649/doc4.xml","form_type":"4"}},{"id":2175319,"issuer":{"id":124310,"kind":"organization","name":"LA JOLLA PHARMACEUTICAL CO","symbol":"LJPC"},"owners":[{"id":45594,"kind":"person","name":"Hearne Michael S","position":1,"cik":"0001759910","reported_name":"Hearne Michael S","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Employee Stock Option (Right to Buy)","published_at":"2022-08-24T20:17:34.000Z","date":"2022-08-22","kind":"disposition_to_issuer","acquired":false,"shares":164,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F3","text":"Pursuant to the terms of the Merger Agreement, immediately prior to the Effective Time, each option to purchase Shares granted under an Issuer equity plan (each, an \"Issuer Stock Option\") that was outstanding and unexercised was cancelled and converted into the right to receive a cash payment equal to the excess, if any, of the Offer Price over the exercise price payable per Share with respect to such Issuer Stock Option."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"Pursuant to the terms of the Merger Agreement, immediately prior to the Effective Time, each option to purchase Shares granted under an Issuer equity plan (each, an \"Issuer Stock Option\") that was outstanding and unexercised was cancelled and converted into the right to receive a cash payment equal to the excess, if any, of the Offer Price over the exercise price payable per Share with respect to such Issuer Stock Option."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F3","text":"Pursuant to the terms of the Merger Agreement, immediately prior to the Effective Time, each option to purchase Shares granted under an Issuer equity plan (each, an \"Issuer Stock Option\") that was outstanding and unexercised was cancelled and converted into the right to receive a cash payment equal to the excess, if any, of the Offer Price over the exercise price payable per Share with respect to such Issuer Stock Option."}],"balance_after":0,"derivative":{"exercise_price":4.44,"underlying":"Common Stock","underlying_shares":164},"source":{"system":"sec-edgar","filing":"0000899243-22-029649","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":18,"url":"https://www.sec.gov/Archives/edgar/data/920465/000089924322029649/doc4.xml","form_type":"4"}},{"id":2175318,"issuer":{"id":124310,"kind":"organization","name":"LA JOLLA PHARMACEUTICAL CO","symbol":"LJPC"},"owners":[{"id":45594,"kind":"person","name":"Hearne Michael S","position":1,"cik":"0001759910","reported_name":"Hearne Michael S","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Employee Stock Option (Right to Buy)","published_at":"2022-08-24T20:17:34.000Z","date":"2022-08-22","kind":"disposition_to_issuer","acquired":false,"shares":173,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F3","text":"Pursuant to the terms of the Merger Agreement, immediately prior to the Effective Time, each option to purchase Shares granted under an Issuer equity plan (each, an \"Issuer Stock Option\") that was outstanding and unexercised was cancelled and converted into the right to receive a cash payment equal to the excess, if any, of the Offer Price over the exercise price payable per Share with respect to such Issuer Stock Option."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"Pursuant to the terms of the Merger Agreement, immediately prior to the Effective Time, each option to purchase Shares granted under an Issuer equity plan (each, an \"Issuer Stock Option\") that was outstanding and unexercised was cancelled and converted into the right to receive a cash payment equal to the excess, if any, of the Offer Price over the exercise price payable per Share with respect to such Issuer Stock Option."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F3","text":"Pursuant to the terms of the Merger Agreement, immediately prior to the Effective Time, each option to purchase Shares granted under an Issuer equity plan (each, an \"Issuer Stock Option\") that was outstanding and unexercised was cancelled and converted into the right to receive a cash payment equal to the excess, if any, of the Offer Price over the exercise price payable per Share with respect to such Issuer Stock Option."}],"balance_after":0,"derivative":{"exercise_price":4.18,"underlying":"Common Stock","underlying_shares":173},"source":{"system":"sec-edgar","filing":"0000899243-22-029649","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":17,"url":"https://www.sec.gov/Archives/edgar/data/920465/000089924322029649/doc4.xml","form_type":"4"}},{"id":2175317,"issuer":{"id":124310,"kind":"organization","name":"LA JOLLA PHARMACEUTICAL CO","symbol":"LJPC"},"owners":[{"id":45594,"kind":"person","name":"Hearne Michael S","position":1,"cik":"0001759910","reported_name":"Hearne Michael S","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Employee Stock Option (Right to Buy)","published_at":"2022-08-24T20:17:34.000Z","date":"2022-08-22","kind":"disposition_to_issuer","acquired":false,"shares":172,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F3","text":"Pursuant to the terms of the Merger Agreement, immediately prior to the Effective Time, each option to purchase Shares granted under an Issuer equity plan (each, an \"Issuer Stock Option\") that was outstanding and unexercised was cancelled and converted into the right to receive a cash payment equal to the excess, if any, of the Offer Price over the exercise price payable per Share with respect to such Issuer Stock Option."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"Pursuant to the terms of the Merger Agreement, immediately prior to the Effective Time, each option to purchase Shares granted under an Issuer equity plan (each, an \"Issuer Stock Option\") that was outstanding and unexercised was cancelled and converted into the right to receive a cash payment equal to the excess, if any, of the Offer Price over the exercise price payable per Share with respect to such Issuer Stock Option."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F3","text":"Pursuant to the terms of the Merger Agreement, immediately prior to the Effective Time, each option to purchase Shares granted under an Issuer equity plan (each, an \"Issuer Stock Option\") that was outstanding and unexercised was cancelled and converted into the right to receive a cash payment equal to the excess, if any, of the Offer Price over the exercise price payable per Share with respect to such Issuer Stock Option."}],"balance_after":0,"derivative":{"exercise_price":4.24,"underlying":"Common Stock","underlying_shares":172},"source":{"system":"sec-edgar","filing":"0000899243-22-029649","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":16,"url":"https://www.sec.gov/Archives/edgar/data/920465/000089924322029649/doc4.xml","form_type":"4"}},{"id":2175316,"issuer":{"id":124310,"kind":"organization","name":"LA JOLLA PHARMACEUTICAL CO","symbol":"LJPC"},"owners":[{"id":45594,"kind":"person","name":"Hearne Michael S","position":1,"cik":"0001759910","reported_name":"Hearne Michael S","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Employee Stock Option (Right to Buy)","published_at":"2022-08-24T20:17:34.000Z","date":"2022-08-22","kind":"disposition_to_issuer","acquired":false,"shares":127,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F3","text":"Pursuant to the terms of the Merger Agreement, immediately prior to the Effective Time, each option to purchase Shares granted under an Issuer equity plan (each, an \"Issuer Stock Option\") that was outstanding and unexercised was cancelled and converted into the right to receive a cash payment equal to the excess, if any, of the Offer Price over the exercise price payable per Share with respect to such Issuer Stock Option."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"Pursuant to the terms of the Merger Agreement, immediately prior to the Effective Time, each option to purchase Shares granted under an Issuer equity plan (each, an \"Issuer Stock Option\") that was outstanding and unexercised was cancelled and converted into the right to receive a cash payment equal to the excess, if any, of the Offer Price over the exercise price payable per Share with respect to such Issuer Stock Option."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F3","text":"Pursuant to the terms of the Merger Agreement, immediately prior to the Effective Time, each option to purchase Shares granted under an Issuer equity plan (each, an \"Issuer Stock Option\") that was outstanding and unexercised was cancelled and converted into the right to receive a cash payment equal to the excess, if any, of the Offer Price over the exercise price payable per Share with respect to such Issuer Stock Option."}],"balance_after":0,"derivative":{"exercise_price":5.71,"underlying":"Common Stock","underlying_shares":127},"source":{"system":"sec-edgar","filing":"0000899243-22-029649","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":15,"url":"https://www.sec.gov/Archives/edgar/data/920465/000089924322029649/doc4.xml","form_type":"4"}},{"id":2175315,"issuer":{"id":124310,"kind":"organization","name":"LA JOLLA PHARMACEUTICAL CO","symbol":"LJPC"},"owners":[{"id":45594,"kind":"person","name":"Hearne Michael S","position":1,"cik":"0001759910","reported_name":"Hearne Michael S","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Employee Stock Option (Right to Buy)","published_at":"2022-08-24T20:17:34.000Z","date":"2022-08-22","kind":"disposition_to_issuer","acquired":false,"shares":139,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F3","text":"Pursuant to the terms of the Merger Agreement, immediately prior to the Effective Time, each option to purchase Shares granted under an Issuer equity plan (each, an \"Issuer Stock Option\") that was outstanding and unexercised was cancelled and converted into the right to receive a cash payment equal to the excess, if any, of the Offer Price over the exercise price payable per Share with respect to such Issuer Stock Option."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"Pursuant to the terms of the Merger Agreement, immediately prior to the Effective Time, each option to purchase Shares granted under an Issuer equity plan (each, an \"Issuer Stock Option\") that was outstanding and unexercised was cancelled and converted into the right to receive a cash payment equal to the excess, if any, of the Offer Price over the exercise price payable per Share with respect to such Issuer Stock Option."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F3","text":"Pursuant to the terms of the Merger Agreement, immediately prior to the Effective Time, each option to purchase Shares granted under an Issuer equity plan (each, an \"Issuer Stock Option\") that was outstanding and unexercised was cancelled and converted into the right to receive a cash payment equal to the excess, if any, of the Offer Price over the exercise price payable per Share with respect to such Issuer Stock Option."}],"balance_after":0,"derivative":{"exercise_price":5.24,"underlying":"Common Stock","underlying_shares":139},"source":{"system":"sec-edgar","filing":"0000899243-22-029649","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":14,"url":"https://www.sec.gov/Archives/edgar/data/920465/000089924322029649/doc4.xml","form_type":"4"}},{"id":2175314,"issuer":{"id":124310,"kind":"organization","name":"LA JOLLA PHARMACEUTICAL CO","symbol":"LJPC"},"owners":[{"id":45594,"kind":"person","name":"Hearne Michael S","position":1,"cik":"0001759910","reported_name":"Hearne Michael S","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Employee Stock Option (Right to Buy)","published_at":"2022-08-24T20:17:34.000Z","date":"2022-08-22","kind":"disposition_to_issuer","acquired":false,"shares":108,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F3","text":"Pursuant to the terms of the Merger Agreement, immediately prior to the Effective Time, each option to purchase Shares granted under an Issuer equity plan (each, an \"Issuer Stock Option\") that was outstanding and unexercised was cancelled and converted into the right to receive a cash payment equal to the excess, if any, of the Offer Price over the exercise price payable per Share with respect to such Issuer Stock Option."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"Pursuant to the terms of the Merger Agreement, immediately prior to the Effective Time, each option to purchase Shares granted under an Issuer equity plan (each, an \"Issuer Stock Option\") that was outstanding and unexercised was cancelled and converted into the right to receive a cash payment equal to the excess, if any, of the Offer Price over the exercise price payable per Share with respect to such Issuer Stock Option."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F3","text":"Pursuant to the terms of the Merger Agreement, immediately prior to the Effective Time, each option to purchase Shares granted under an Issuer equity plan (each, an \"Issuer Stock Option\") that was outstanding and unexercised was cancelled and converted into the right to receive a cash payment equal to the excess, if any, of the Offer Price over the exercise price payable per Share with respect to such Issuer Stock Option."}],"balance_after":0,"derivative":{"exercise_price":6.71,"underlying":"Common Stock","underlying_shares":108},"source":{"system":"sec-edgar","filing":"0000899243-22-029649","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":13,"url":"https://www.sec.gov/Archives/edgar/data/920465/000089924322029649/doc4.xml","form_type":"4"}},{"id":2175313,"issuer":{"id":124310,"kind":"organization","name":"LA JOLLA PHARMACEUTICAL CO","symbol":"LJPC"},"owners":[{"id":45594,"kind":"person","name":"Hearne Michael S","position":1,"cik":"0001759910","reported_name":"Hearne Michael S","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Employee Stock Option (Right to Buy)","published_at":"2022-08-24T20:17:34.000Z","date":"2022-08-22","kind":"disposition_to_issuer","acquired":false,"shares":118,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F3","text":"Pursuant to the terms of the Merger Agreement, immediately prior to the Effective Time, each option to purchase Shares granted under an Issuer equity plan (each, an \"Issuer Stock Option\") that was outstanding and unexercised was cancelled and converted into the right to receive a cash payment equal to the excess, if any, of the Offer Price over the exercise price payable per Share with respect to such Issuer Stock Option."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"Pursuant to the terms of the Merger Agreement, immediately prior to the Effective Time, each option to purchase Shares granted under an Issuer equity plan (each, an \"Issuer Stock Option\") that was outstanding and unexercised was cancelled and converted into the right to receive a cash payment equal to the excess, if any, of the Offer Price over the exercise price payable per Share with respect to such Issuer Stock Option."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F3","text":"Pursuant to the terms of the Merger Agreement, immediately prior to the Effective Time, each option to purchase Shares granted under an Issuer equity plan (each, an \"Issuer Stock Option\") that was outstanding and unexercised was cancelled and converted into the right to receive a cash payment equal to the excess, if any, of the Offer Price over the exercise price payable per Share with respect to such Issuer Stock Option."}],"balance_after":0,"derivative":{"exercise_price":6.12,"underlying":"Common Stock","underlying_shares":118},"source":{"system":"sec-edgar","filing":"0000899243-22-029649","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":12,"url":"https://www.sec.gov/Archives/edgar/data/920465/000089924322029649/doc4.xml","form_type":"4"}},{"id":2175312,"issuer":{"id":124310,"kind":"organization","name":"LA JOLLA PHARMACEUTICAL CO","symbol":"LJPC"},"owners":[{"id":45594,"kind":"person","name":"Hearne Michael S","position":1,"cik":"0001759910","reported_name":"Hearne Michael S","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Employee Stock Option (Right to Buy)","published_at":"2022-08-24T20:17:34.000Z","date":"2022-08-22","kind":"disposition_to_issuer","acquired":false,"shares":136,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F3","text":"Pursuant to the terms of the Merger Agreement, immediately prior to the Effective Time, each option to purchase Shares granted under an Issuer equity plan (each, an \"Issuer Stock Option\") that was outstanding and unexercised was cancelled and converted into the right to receive a cash payment equal to the excess, if any, of the Offer Price over the exercise price payable per Share with respect to such Issuer Stock Option."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"Pursuant to the terms of the Merger Agreement, immediately prior to the Effective Time, each option to purchase Shares granted under an Issuer equity plan (each, an \"Issuer Stock Option\") that was outstanding and unexercised was cancelled and converted into the right to receive a cash payment equal to the excess, if any, of the Offer Price over the exercise price payable per Share with respect to such Issuer Stock Option."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F3","text":"Pursuant to the terms of the Merger Agreement, immediately prior to the Effective Time, each option to purchase Shares granted under an Issuer equity plan (each, an \"Issuer Stock Option\") that was outstanding and unexercised was cancelled and converted into the right to receive a cash payment equal to the excess, if any, of the Offer Price over the exercise price payable per Share with respect to such Issuer Stock Option."}],"balance_after":0,"derivative":{"exercise_price":5.35,"underlying":"Common Stock","underlying_shares":136},"source":{"system":"sec-edgar","filing":"0000899243-22-029649","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":11,"url":"https://www.sec.gov/Archives/edgar/data/920465/000089924322029649/doc4.xml","form_type":"4"}},{"id":2175311,"issuer":{"id":124310,"kind":"organization","name":"LA JOLLA PHARMACEUTICAL CO","symbol":"LJPC"},"owners":[{"id":45594,"kind":"person","name":"Hearne Michael S","position":1,"cik":"0001759910","reported_name":"Hearne Michael S","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Employee Stock Option (Right to Buy)","published_at":"2022-08-24T20:17:34.000Z","date":"2022-08-22","kind":"disposition_to_issuer","acquired":false,"shares":1648,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F3","text":"Pursuant to the terms of the Merger Agreement, immediately prior to the Effective Time, each option to purchase Shares granted under an Issuer equity plan (each, an \"Issuer Stock Option\") that was outstanding and unexercised was cancelled and converted into the right to receive a cash payment equal to the excess, if any, of the Offer Price over the exercise price payable per Share with respect to such Issuer Stock Option."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"Pursuant to the terms of the Merger Agreement, immediately prior to the Effective Time, each option to purchase Shares granted under an Issuer equity plan (each, an \"Issuer Stock Option\") that was outstanding and unexercised was cancelled and converted into the right to receive a cash payment equal to the excess, if any, of the Offer Price over the exercise price payable per Share with respect to such Issuer Stock Option."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F3","text":"Pursuant to the terms of the Merger Agreement, immediately prior to the Effective Time, each option to purchase Shares granted under an Issuer equity plan (each, an \"Issuer Stock Option\") that was outstanding and unexercised was cancelled and converted into the right to receive a cash payment equal to the excess, if any, of the Offer Price over the exercise price payable per Share with respect to such Issuer Stock Option."}],"balance_after":0,"derivative":{"exercise_price":3.88,"underlying":"Common Stock","underlying_shares":1648},"source":{"system":"sec-edgar","filing":"0000899243-22-029649","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":10,"url":"https://www.sec.gov/Archives/edgar/data/920465/000089924322029649/doc4.xml","form_type":"4"}},{"id":2175310,"issuer":{"id":124310,"kind":"organization","name":"LA JOLLA PHARMACEUTICAL CO","symbol":"LJPC"},"owners":[{"id":45594,"kind":"person","name":"Hearne Michael S","position":1,"cik":"0001759910","reported_name":"Hearne Michael S","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Employee Stock Option (Right to Buy)","published_at":"2022-08-24T20:17:34.000Z","date":"2022-08-22","kind":"disposition_to_issuer","acquired":false,"shares":147,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F3","text":"Pursuant to the terms of the Merger Agreement, immediately prior to the Effective Time, each option to purchase Shares granted under an Issuer equity plan (each, an \"Issuer Stock Option\") that was outstanding and unexercised was cancelled and converted into the right to receive a cash payment equal to the excess, if any, of the Offer Price over the exercise price payable per Share with respect to such Issuer Stock Option."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"Pursuant to the terms of the Merger Agreement, immediately prior to the Effective Time, each option to purchase Shares granted under an Issuer equity plan (each, an \"Issuer Stock Option\") that was outstanding and unexercised was cancelled and converted into the right to receive a cash payment equal to the excess, if any, of the Offer Price over the exercise price payable per Share with respect to such Issuer Stock Option."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F3","text":"Pursuant to the terms of the Merger Agreement, immediately prior to the Effective Time, each option to purchase Shares granted under an Issuer equity plan (each, an \"Issuer Stock Option\") that was outstanding and unexercised was cancelled and converted into the right to receive a cash payment equal to the excess, if any, of the Offer Price over the exercise price payable per Share with respect to such Issuer Stock Option."}],"balance_after":0,"derivative":{"exercise_price":4.5,"underlying":"Common Stock","underlying_shares":147},"source":{"system":"sec-edgar","filing":"0000899243-22-029649","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":9,"url":"https://www.sec.gov/Archives/edgar/data/920465/000089924322029649/doc4.xml","form_type":"4"}},{"id":2175309,"issuer":{"id":124310,"kind":"organization","name":"LA JOLLA PHARMACEUTICAL CO","symbol":"LJPC"},"owners":[{"id":45594,"kind":"person","name":"Hearne Michael S","position":1,"cik":"0001759910","reported_name":"Hearne Michael S","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Employee Stock Option (Right to Buy)","published_at":"2022-08-24T20:17:34.000Z","date":"2022-08-22","kind":"disposition_to_issuer","acquired":false,"shares":52191,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F3","text":"Pursuant to the terms of the Merger Agreement, immediately prior to the Effective Time, each option to purchase Shares granted under an Issuer equity plan (each, an \"Issuer Stock Option\") that was outstanding and unexercised was cancelled and converted into the right to receive a cash payment equal to the excess, if any, of the Offer Price over the exercise price payable per Share with respect to such Issuer Stock Option."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"Pursuant to the terms of the Merger Agreement, immediately prior to the Effective Time, each option to purchase Shares granted under an Issuer equity plan (each, an \"Issuer Stock Option\") that was outstanding and unexercised was cancelled and converted into the right to receive a cash payment equal to the excess, if any, of the Offer Price over the exercise price payable per Share with respect to such Issuer Stock Option."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F3","text":"Pursuant to the terms of the Merger Agreement, immediately prior to the Effective Time, each option to purchase Shares granted under an Issuer equity plan (each, an \"Issuer Stock Option\") that was outstanding and unexercised was cancelled and converted into the right to receive a cash payment equal to the excess, if any, of the Offer Price over the exercise price payable per Share with respect to such Issuer Stock Option."}],"balance_after":0,"derivative":{"exercise_price":4.53,"underlying":"Common Stock","underlying_shares":52191},"source":{"system":"sec-edgar","filing":"0000899243-22-029649","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":8,"url":"https://www.sec.gov/Archives/edgar/data/920465/000089924322029649/doc4.xml","form_type":"4"}},{"id":2175308,"issuer":{"id":124310,"kind":"organization","name":"LA JOLLA PHARMACEUTICAL CO","symbol":"LJPC"},"owners":[{"id":45594,"kind":"person","name":"Hearne Michael S","position":1,"cik":"0001759910","reported_name":"Hearne Michael S","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Employee Stock Option (Right to Buy)","published_at":"2022-08-24T20:17:34.000Z","date":"2022-08-22","kind":"disposition_to_issuer","acquired":false,"shares":134,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F3","text":"Pursuant to the terms of the Merger Agreement, immediately prior to the Effective Time, each option to purchase Shares granted under an Issuer equity plan (each, an \"Issuer Stock Option\") that was outstanding and unexercised was cancelled and converted into the right to receive a cash payment equal to the excess, if any, of the Offer Price over the exercise price payable per Share with respect to such Issuer Stock Option."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"Pursuant to the terms of the Merger Agreement, immediately prior to the Effective Time, each option to purchase Shares granted under an Issuer equity plan (each, an \"Issuer Stock Option\") that was outstanding and unexercised was cancelled and converted into the right to receive a cash payment equal to the excess, if any, of the Offer Price over the exercise price payable per Share with respect to such Issuer Stock Option."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F3","text":"Pursuant to the terms of the Merger Agreement, immediately prior to the Effective Time, each option to purchase Shares granted under an Issuer equity plan (each, an \"Issuer Stock Option\") that was outstanding and unexercised was cancelled and converted into the right to receive a cash payment equal to the excess, if any, of the Offer Price over the exercise price payable per Share with respect to such Issuer Stock Option."}],"balance_after":0,"derivative":{"exercise_price":4.97,"underlying":"Common Stock","underlying_shares":134},"source":{"system":"sec-edgar","filing":"0000899243-22-029649","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":7,"url":"https://www.sec.gov/Archives/edgar/data/920465/000089924322029649/doc4.xml","form_type":"4"}},{"id":2175307,"issuer":{"id":124310,"kind":"organization","name":"LA JOLLA PHARMACEUTICAL CO","symbol":"LJPC"},"owners":[{"id":45594,"kind":"person","name":"Hearne Michael S","position":1,"cik":"0001759910","reported_name":"Hearne Michael S","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Employee Stock Option (Right to Buy)","published_at":"2022-08-24T20:17:34.000Z","date":"2022-08-22","kind":"disposition_to_issuer","acquired":false,"shares":141,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F3","text":"Pursuant to the terms of the Merger Agreement, immediately prior to the Effective Time, each option to purchase Shares granted under an Issuer equity plan (each, an \"Issuer Stock Option\") that was outstanding and unexercised was cancelled and converted into the right to receive a cash payment equal to the excess, if any, of the Offer Price over the exercise price payable per Share with respect to such Issuer Stock Option."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"Pursuant to the terms of the Merger Agreement, immediately prior to the Effective Time, each option to purchase Shares granted under an Issuer equity plan (each, an \"Issuer Stock Option\") that was outstanding and unexercised was cancelled and converted into the right to receive a cash payment equal to the excess, if any, of the Offer Price over the exercise price payable per Share with respect to such Issuer Stock Option."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F3","text":"Pursuant to the terms of the Merger Agreement, immediately prior to the Effective Time, each option to purchase Shares granted under an Issuer equity plan (each, an \"Issuer Stock Option\") that was outstanding and unexercised was cancelled and converted into the right to receive a cash payment equal to the excess, if any, of the Offer Price over the exercise price payable per Share with respect to such Issuer Stock Option."}],"balance_after":0,"derivative":{"exercise_price":4.68,"underlying":"Common Stock","underlying_shares":141},"source":{"system":"sec-edgar","filing":"0000899243-22-029649","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/920465/000089924322029649/doc4.xml","form_type":"4"}},{"id":2175306,"issuer":{"id":124310,"kind":"organization","name":"LA JOLLA PHARMACEUTICAL CO","symbol":"LJPC"},"owners":[{"id":45594,"kind":"person","name":"Hearne Michael S","position":1,"cik":"0001759910","reported_name":"Hearne Michael S","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Employee Stock Option (Right to Buy)","published_at":"2022-08-24T20:17:34.000Z","date":"2022-08-22","kind":"disposition_to_issuer","acquired":false,"shares":196,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F3","text":"Pursuant to the terms of the Merger Agreement, immediately prior to the Effective Time, each option to purchase Shares granted under an Issuer equity plan (each, an \"Issuer Stock Option\") that was outstanding and unexercised was cancelled and converted into the right to receive a cash payment equal to the excess, if any, of the Offer Price over the exercise price payable per Share with respect to such Issuer Stock Option."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"Pursuant to the terms of the Merger Agreement, immediately prior to the Effective Time, each option to purchase Shares granted under an Issuer equity plan (each, an \"Issuer Stock Option\") that was outstanding and unexercised was cancelled and converted into the right to receive a cash payment equal to the excess, if any, of the Offer Price over the exercise price payable per Share with respect to such Issuer Stock Option."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F3","text":"Pursuant to the terms of the Merger Agreement, immediately prior to the Effective Time, each option to purchase Shares granted under an Issuer equity plan (each, an \"Issuer Stock Option\") that was outstanding and unexercised was cancelled and converted into the right to receive a cash payment equal to the excess, if any, of the Offer Price over the exercise price payable per Share with respect to such Issuer Stock Option."}],"balance_after":0,"derivative":{"exercise_price":3.4,"underlying":"Common Stock","underlying_shares":196},"source":{"system":"sec-edgar","filing":"0000899243-22-029649","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/920465/000089924322029649/doc4.xml","form_type":"4"}},{"id":2175305,"issuer":{"id":124310,"kind":"organization","name":"LA JOLLA PHARMACEUTICAL CO","symbol":"LJPC"},"owners":[{"id":45594,"kind":"person","name":"Hearne Michael S","position":1,"cik":"0001759910","reported_name":"Hearne Michael S","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Employee Stock Option (Right to Buy)","published_at":"2022-08-24T20:17:34.000Z","date":"2022-08-22","kind":"disposition_to_issuer","acquired":false,"shares":169,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F3","text":"Pursuant to the terms of the Merger Agreement, immediately prior to the Effective Time, each option to purchase Shares granted under an Issuer equity plan (each, an \"Issuer Stock Option\") that was outstanding and unexercised was cancelled and converted into the right to receive a cash payment equal to the excess, if any, of the Offer Price over the exercise price payable per Share with respect to such Issuer Stock Option."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"Pursuant to the terms of the Merger Agreement, immediately prior to the Effective Time, each option to purchase Shares granted under an Issuer equity plan (each, an \"Issuer Stock Option\") that was outstanding and unexercised was cancelled and converted into the right to receive a cash payment equal to the excess, if any, of the Offer Price over the exercise price payable per Share with respect to such Issuer Stock Option."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F3","text":"Pursuant to the terms of the Merger Agreement, immediately prior to the Effective Time, each option to purchase Shares granted under an Issuer equity plan (each, an \"Issuer Stock Option\") that was outstanding and unexercised was cancelled and converted into the right to receive a cash payment equal to the excess, if any, of the Offer Price over the exercise price payable per Share with respect to such Issuer Stock Option."}],"balance_after":0,"derivative":{"exercise_price":3.91,"underlying":"Common Stock","underlying_shares":169},"source":{"system":"sec-edgar","filing":"0000899243-22-029649","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/920465/000089924322029649/doc4.xml","form_type":"4"}},{"id":2175304,"issuer":{"id":124310,"kind":"organization","name":"LA JOLLA PHARMACEUTICAL CO","symbol":"LJPC"},"owners":[{"id":45594,"kind":"person","name":"Hearne Michael S","position":1,"cik":"0001759910","reported_name":"Hearne Michael S","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Employee Stock Option (Right to Buy)","published_at":"2022-08-24T20:17:34.000Z","date":"2022-08-22","kind":"disposition_to_issuer","acquired":false,"shares":100000,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F3","text":"Pursuant to the terms of the Merger Agreement, immediately prior to the Effective Time, each option to purchase Shares granted under an Issuer equity plan (each, an \"Issuer Stock Option\") that was outstanding and unexercised was cancelled and converted into the right to receive a cash payment equal to the excess, if any, of the Offer Price over the exercise price payable per Share with respect to such Issuer Stock Option."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"Pursuant to the terms of the Merger Agreement, immediately prior to the Effective Time, each option to purchase Shares granted under an Issuer equity plan (each, an \"Issuer Stock Option\") that was outstanding and unexercised was cancelled and converted into the right to receive a cash payment equal to the excess, if any, of the Offer Price over the exercise price payable per Share with respect to such Issuer Stock Option."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F3","text":"Pursuant to the terms of the Merger Agreement, immediately prior to the Effective Time, each option to purchase Shares granted under an Issuer equity plan (each, an \"Issuer Stock Option\") that was outstanding and unexercised was cancelled and converted into the right to receive a cash payment equal to the excess, if any, of the Offer Price over the exercise price payable per Share with respect to such Issuer Stock Option."}],"balance_after":0,"derivative":{"exercise_price":4.55,"underlying":"Common Stock","underlying_shares":100000},"source":{"system":"sec-edgar","filing":"0000899243-22-029649","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/920465/000089924322029649/doc4.xml","form_type":"4"}},{"id":2175303,"issuer":{"id":124310,"kind":"organization","name":"LA JOLLA PHARMACEUTICAL CO","symbol":"LJPC"},"owners":[{"id":45594,"kind":"person","name":"Hearne Michael S","position":1,"cik":"0001759910","reported_name":"Hearne Michael S","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Common Stock","published_at":"2022-08-24T20:17:34.000Z","date":"2022-08-22","kind":"other","acquired":false,"shares":9607934,"price":6.23,"value":59857428.82,"ownership":{"direct":false,"nature":"BY LP"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This Form 4 reports securities disposed of pursuant to the terms of the Agreement and Plan of Merger (the \"Merger Agreement\"), dated as of July 10, 2022, by and among the Issuer, Innoviva, Inc., a Delaware corporation (\"Parent\"), and Innoviva Acquisition Sub, Inc., a Delaware corporation and a wholly-owned subsidiary of the Parent (\"Purchaser\"), to which Purchaser completed a tender offer for shares of common stock of the Issuer, $0.0001 par value per share (each, a \"Share\"), and thereafter merged with and into the Issuer (the \"Merger\") effective as of August 22, 2022 (the \"Effective Time\"). At the Effective Time, each issued and outstanding Share was converted into the right to receive $6.23 per Share, in cash, without interest (the \"Offer Price\") and subject to any withholding of taxes, upon the terms and subject to the conditions of the Merger Agreement. From and after the Effective Time, all Shares were no longer outstanding and were automatically cancelled."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"This Form 4 reports securities disposed of pursuant to the terms of the Agreement and Plan of Merger (the \"Merger Agreement\"), dated as of July 10, 2022, by and among the Issuer, Innoviva, Inc., a Delaware corporation (\"Parent\"), and Innoviva Acquisition Sub, Inc., a Delaware corporation and a wholly-owned subsidiary of the Parent (\"Purchaser\"), to which Purchaser completed a tender offer for shares of common stock of the Issuer, $0.0001 par value per share (each, a \"Share\"), and thereafter merged with and into the Issuer (the \"Merger\") effective as of August 22, 2022 (the \"Effective Time\"). At the Effective Time, each issued and outstanding Share was converted into the right to receive $6.23 per Share, in cash, without interest (the \"Offer Price\") and subject to any withholding of taxes, upon the terms and subject to the conditions of the Merger Agreement. From and after the Effective Time, all Shares were no longer outstanding and were automatically cancelled."},{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F2","text":"The Shares are beneficially owned by Tang Capital Partners, LP (\"TCP\"). Tang Capital Management, LLC (\"TCM\") is the general partner of TCP. Michael Hearne is the Chief Financial Officer of La Jolla Pharmaceutical Company, as well as the Chief Financial Officer of TCM. Mr. Hearne has a pecuniary interest in the shares beneficially held by TCP."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"The Shares are beneficially owned by Tang Capital Partners, LP (\"TCP\"). Tang Capital Management, LLC (\"TCM\") is the general partner of TCP. Michael Hearne is the Chief Financial Officer of La Jolla Pharmaceutical Company, as well as the Chief Financial Officer of TCM. Mr. Hearne has a pecuniary interest in the shares beneficially held by TCP."}],"balance_after":0,"source":{"system":"sec-edgar","filing":"0000899243-22-029649","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/920465/000089924322029649/doc4.xml","form_type":"4"}},{"id":2175302,"issuer":{"id":124310,"kind":"organization","name":"LA JOLLA PHARMACEUTICAL CO","symbol":"LJPC"},"owners":[{"id":45594,"kind":"person","name":"Hearne Michael S","position":1,"cik":"0001759910","reported_name":"Hearne Michael S","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Common Stock","published_at":"2022-08-24T20:17:34.000Z","date":"2022-08-22","kind":"disposition_to_issuer","acquired":false,"shares":10186,"price":6.23,"value":63458.78,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This Form 4 reports securities disposed of pursuant to the terms of the Agreement and Plan of Merger (the \"Merger Agreement\"), dated as of July 10, 2022, by and among the Issuer, Innoviva, Inc., a Delaware corporation (\"Parent\"), and Innoviva Acquisition Sub, Inc., a Delaware corporation and a wholly-owned subsidiary of the Parent (\"Purchaser\"), to which Purchaser completed a tender offer for shares of common stock of the Issuer, $0.0001 par value per share (each, a \"Share\"), and thereafter merged with and into the Issuer (the \"Merger\") effective as of August 22, 2022 (the \"Effective Time\"). At the Effective Time, each issued and outstanding Share was converted into the right to receive $6.23 per Share, in cash, without interest (the \"Offer Price\") and subject to any withholding of taxes, upon the terms and subject to the conditions of the Merger Agreement. From and after the Effective Time, all Shares were no longer outstanding and were automatically cancelled."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"This Form 4 reports securities disposed of pursuant to the terms of the Agreement and Plan of Merger (the \"Merger Agreement\"), dated as of July 10, 2022, by and among the Issuer, Innoviva, Inc., a Delaware corporation (\"Parent\"), and Innoviva Acquisition Sub, Inc., a Delaware corporation and a wholly-owned subsidiary of the Parent (\"Purchaser\"), to which Purchaser completed a tender offer for shares of common stock of the Issuer, $0.0001 par value per share (each, a \"Share\"), and thereafter merged with and into the Issuer (the \"Merger\") effective as of August 22, 2022 (the \"Effective Time\"). At the Effective Time, each issued and outstanding Share was converted into the right to receive $6.23 per Share, in cash, without interest (the \"Offer Price\") and subject to any withholding of taxes, upon the terms and subject to the conditions of the Merger Agreement. From and after the Effective Time, all Shares were no longer outstanding and were automatically cancelled."}],"balance_after":0,"source":{"system":"sec-edgar","filing":"0000899243-22-029649","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/920465/000089924322029649/doc4.xml","form_type":"4"}},{"id":2175335,"issuer":{"id":124310,"kind":"organization","name":"LA JOLLA PHARMACEUTICAL CO","symbol":"LJPC"},"owners":[{"id":18814,"kind":"person","name":"TANG KEVIN","position":1,"cik":"0001178579","reported_name":"TANG KEVIN C","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":82742,"kind":"organization","name":"TANG CAPITAL PARTNERS LP","position":2,"cik":"0001191935","reported_name":"TANG CAPITAL PARTNERS LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":18815,"kind":"organization","name":"TANG CAPITAL MANAGEMENT LLC","position":3,"cik":"0001232621","reported_name":"TANG CAPITAL MANAGEMENT LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":45594,"kind":"person","name":"Hearne Michael S","position":4,"cik":"0001759910","reported_name":"Hearne Michael S","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Series C-1(2) Convertible Preferred Stock","published_at":"2022-08-24T16:02:16.000Z","date":"2022-08-22","kind":"other","acquired":false,"shares":3519.315,"ownership":{"direct":false,"nature":"By LP"},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F3","text":"Pursuant to the Merger Agreement, at the Effective Time, each share of Series C-1(2) Convertible Preferred Stock was converted into the right to receive an amount in cash equal to 1,724.04 times the Offer Price."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"Pursuant to the Merger Agreement, at the Effective Time, each share of Series C-1(2) Convertible Preferred Stock was converted into the right to receive an amount in cash equal to 1,724.04 times the Offer Price."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"Pursuant to the Merger Agreement, at the Effective Time, each share of Series C-1(2) Convertible Preferred Stock was converted into the right to receive an amount in cash equal to 1,724.04 times the Offer Price."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F3","text":"Pursuant to the Merger Agreement, at the Effective Time, each share of Series C-1(2) Convertible Preferred Stock was converted into the right to receive an amount in cash equal to 1,724.04 times the Offer Price."},{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F2","text":"The shares are beneficially owned by Tang Capital Partners, LP (\"TCP\"). Kevin Tang is the sole manager of Tang Capital Management, LLC (\"TCM\"), which is the general partner of TCP. Michael Hearne is the Chief Financial Officer of La Jolla Pharmaceutical Company, as well as Chief Financial Officer of TCM. Mr. Tang and Mr. Hearne each have a pecuniary interest in the shares beneficially held by TCP."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"The shares are beneficially owned by Tang Capital Partners, LP (\"TCP\"). Kevin Tang is the sole manager of Tang Capital Management, LLC (\"TCM\"), which is the general partner of TCP. Michael Hearne is the Chief Financial Officer of La Jolla Pharmaceutical Company, as well as Chief Financial Officer of TCM. Mr. Tang and Mr. Hearne each have a pecuniary interest in the shares beneficially held by TCP."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":6067439},"source":{"system":"sec-edgar","filing":"0001209191-22-047314","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/920465/000120919122047314/doc4.xml","form_type":"4"}},{"id":2175334,"issuer":{"id":124310,"kind":"organization","name":"LA JOLLA PHARMACEUTICAL CO","symbol":"LJPC"},"owners":[{"id":18814,"kind":"person","name":"TANG KEVIN","position":1,"cik":"0001178579","reported_name":"TANG KEVIN C","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":82742,"kind":"organization","name":"TANG CAPITAL PARTNERS LP","position":2,"cik":"0001191935","reported_name":"TANG CAPITAL PARTNERS LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":18815,"kind":"organization","name":"TANG CAPITAL MANAGEMENT LLC","position":3,"cik":"0001232621","reported_name":"TANG CAPITAL MANAGEMENT LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":45594,"kind":"person","name":"Hearne Michael S","position":4,"cik":"0001759910","reported_name":"Hearne Michael S","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Common Stock","published_at":"2022-08-24T16:02:16.000Z","date":"2022-08-22","kind":"other","acquired":false,"shares":9607934,"price":6.23,"value":59857428.82,"ownership":{"direct":false,"nature":"By LP"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This Form 4 reports securities disposed of pursuant to the terms of the Agreement and Plan of Merger (the \"Merger Agreement\"), dated as of July 10, 2022, by and among the Issuer, Innoviva, Inc., a Delaware corporation (\"Parent\"), and Innoviva Acquisition Sub, Inc., a Delaware corporation and a wholly-owned subsidiary of the Parent (\"Purchaser\"), to which Purchaser completed a tender offer for shares of common stock of the Issuer, $0.0001 par value per share (each, a \"Share\"), and thereafter merged with and into the Issuer (the \"Merger\") effective as of August 22, 2022 (the \"Effective Time\"). At the Effective Time, each issued and outstanding Share was converted into the right to receive $6.23 per Share, in cash, without interest (the \"Offer Price\") and subject to any withholding of taxes, upon the terms and subject to the conditions of the Merger Agreement. From and after the Effective Time, all Shares were no longer outstanding and were automatically cancelled."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"This Form 4 reports securities disposed of pursuant to the terms of the Agreement and Plan of Merger (the \"Merger Agreement\"), dated as of July 10, 2022, by and among the Issuer, Innoviva, Inc., a Delaware corporation (\"Parent\"), and Innoviva Acquisition Sub, Inc., a Delaware corporation and a wholly-owned subsidiary of the Parent (\"Purchaser\"), to which Purchaser completed a tender offer for shares of common stock of the Issuer, $0.0001 par value per share (each, a \"Share\"), and thereafter merged with and into the Issuer (the \"Merger\") effective as of August 22, 2022 (the \"Effective Time\"). At the Effective Time, each issued and outstanding Share was converted into the right to receive $6.23 per Share, in cash, without interest (the \"Offer Price\") and subject to any withholding of taxes, upon the terms and subject to the conditions of the Merger Agreement. From and after the Effective Time, all Shares were no longer outstanding and were automatically cancelled."},{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F2","text":"The shares are beneficially owned by Tang Capital Partners, LP (\"TCP\"). Kevin Tang is the sole manager of Tang Capital Management, LLC (\"TCM\"), which is the general partner of TCP. Michael Hearne is the Chief Financial Officer of La Jolla Pharmaceutical Company, as well as Chief Financial Officer of TCM. Mr. Tang and Mr. Hearne each have a pecuniary interest in the shares beneficially held by TCP."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"The shares are beneficially owned by Tang Capital Partners, LP (\"TCP\"). Kevin Tang is the sole manager of Tang Capital Management, LLC (\"TCM\"), which is the general partner of TCP. Michael Hearne is the Chief Financial Officer of La Jolla Pharmaceutical Company, as well as Chief Financial Officer of TCM. Mr. Tang and Mr. Hearne each have a pecuniary interest in the shares beneficially held by TCP."}],"balance_after":0,"source":{"system":"sec-edgar","filing":"0001209191-22-047314","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/920465/000120919122047314/doc4.xml","form_type":"4"}},{"id":2215685,"issuer":{"id":124310,"kind":"organization","name":"LA JOLLA PHARMACEUTICAL CO","symbol":"LJPC"},"owners":[{"id":45594,"kind":"person","name":"Hearne Michael S","position":1,"cik":"0001759910","reported_name":"Hearne Michael S","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Employee Stock Option (Right to Buy)","published_at":"2022-07-05T17:51:27.000Z","date":"2022-06-30","kind":"grant","acquired":true,"shares":236,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"The stock options vest and become exercisable with respect to 25% of the underlying shares on the one-year anniversary of the grant date and then vest and become exercisable ratably on a monthly basis over the next three years."}],"balance_after":236,"derivative":{"exercise_price":3.19,"expiration_date":"2032-06-30","underlying":"Common Stock","underlying_shares":236},"source":{"system":"sec-edgar","filing":"0001209191-22-040873","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/920465/000120919122040873/doc4.xml","form_type":"4"}},{"id":2215684,"issuer":{"id":124310,"kind":"organization","name":"LA JOLLA PHARMACEUTICAL CO","symbol":"LJPC"},"owners":[{"id":45594,"kind":"person","name":"Hearne Michael S","position":1,"cik":"0001759910","reported_name":"Hearne Michael S","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Common Stock","published_at":"2022-07-05T17:51:27.000Z","date":"2022-06-30","kind":"grant","acquired":true,"shares":236,"price":2.7115,"value":639.914,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"These shares were acquired on 6/30/2022 through the La Jolla Pharmaceutical Company 2018 Employee Stock Purchase Plan in a transaction that was exempt under both Rule 16b-3(d) and Rule 16b-3(c)."}],"balance_after":10186,"source":{"system":"sec-edgar","filing":"0001209191-22-040873","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/920465/000120919122040873/doc4.xml","form_type":"4"}},{"id":2228791,"issuer":{"id":124310,"kind":"organization","name":"LA JOLLA PHARMACEUTICAL CO","symbol":"LJPC"},"owners":[{"id":45594,"kind":"person","name":"Hearne Michael S","position":1,"cik":"0001759910","reported_name":"Hearne Michael S","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Employee Stock Option (Right to Buy)","published_at":"2022-06-17T17:05:37.000Z","date":"2022-06-15","kind":"grant","acquired":true,"shares":236,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"The stock options vest and become exercisable with respect to 25% of the underlying shares on the one-year anniversary of the grant date and then vest and become exercisable ratably on a monthly basis over the next three years."}],"balance_after":236,"derivative":{"exercise_price":3.2,"expiration_date":"2032-06-15","underlying":"Common Stock","underlying_shares":236},"source":{"system":"sec-edgar","filing":"0001209191-22-037956","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/920465/000120919122037956/doc4.xml","form_type":"4"}},{"id":2228790,"issuer":{"id":124310,"kind":"organization","name":"LA JOLLA PHARMACEUTICAL CO","symbol":"LJPC"},"owners":[{"id":45594,"kind":"person","name":"Hearne Michael S","position":1,"cik":"0001759910","reported_name":"Hearne Michael S","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Common Stock","published_at":"2022-06-17T17:05:37.000Z","date":"2022-06-15","kind":"grant","acquired":true,"shares":236,"price":2.72,"value":641.92,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"These shares were acquired on 6/15/2022 through the La Jolla Pharmaceutical Company 2018 Employee Stock Purchase Plan in a transaction that was exempt under both Rule 16b-3(d) and Rule 16b-3(c)."}],"balance_after":9950,"source":{"system":"sec-edgar","filing":"0001209191-22-037956","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/920465/000120919122037956/doc4.xml","form_type":"4"}},{"id":2248181,"issuer":{"id":124310,"kind":"organization","name":"LA JOLLA PHARMACEUTICAL CO","symbol":"LJPC"},"owners":[{"id":45594,"kind":"person","name":"Hearne Michael S","position":1,"cik":"0001759910","reported_name":"Hearne Michael S","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Employee Stock Option (Right to Buy)","published_at":"2022-06-02T17:05:16.000Z","date":"2022-05-31","kind":"grant","acquired":true,"shares":189,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"The stock options vest and become exercisable with respect to 25% of the underlying shares on the one-year anniversary of the grant date and then vest and become exercisable ratably on a monthly basis over the next three years."}],"balance_after":189,"derivative":{"exercise_price":4.01,"expiration_date":"2032-05-31","underlying":"Common Stock","underlying_shares":189},"source":{"system":"sec-edgar","filing":"0001209191-22-033597","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/920465/000120919122033597/doc4.xml","form_type":"4"}},{"id":2248180,"issuer":{"id":124310,"kind":"organization","name":"LA JOLLA PHARMACEUTICAL CO","symbol":"LJPC"},"owners":[{"id":45594,"kind":"person","name":"Hearne Michael S","position":1,"cik":"0001759910","reported_name":"Hearne Michael S","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Common Stock","published_at":"2022-06-02T17:05:16.000Z","date":"2022-05-31","kind":"grant","acquired":true,"shares":189,"price":3.4085,"value":644.2065,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"These shares were acquired on 5/31/2022 through the La Jolla Pharmaceutical Company 2018 Employee Stock Purchase Plan in a transaction that was exempt under both Rule 16b-3(d) and Rule 16b-3(c)."}],"balance_after":9714,"source":{"system":"sec-edgar","filing":"0001209191-22-033597","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/920465/000120919122033597/doc4.xml","form_type":"4"}},{"id":2268993,"issuer":{"id":124310,"kind":"organization","name":"LA JOLLA PHARMACEUTICAL CO","symbol":"LJPC"},"owners":[{"id":45594,"kind":"person","name":"Hearne Michael S","position":1,"cik":"0001759910","reported_name":"Hearne Michael S","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Employee Stock Option (Right to Buy)","published_at":"2022-05-17T17:07:17.000Z","date":"2022-05-13","kind":"grant","acquired":true,"shares":188,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"The stock options vest and become exercisable with respect to 25% of the underlying shares on the one-year anniversary of the grant date and then vest and become exercisable ratably on a monthly basis over the next three years."}],"balance_after":188,"derivative":{"exercise_price":4.01,"expiration_date":"2032-05-13","underlying":"Common Stock","underlying_shares":188},"source":{"system":"sec-edgar","filing":"0001209191-22-029751","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/920465/000120919122029751/doc4.xml","form_type":"4"}},{"id":2268992,"issuer":{"id":124310,"kind":"organization","name":"LA JOLLA PHARMACEUTICAL CO","symbol":"LJPC"},"owners":[{"id":45594,"kind":"person","name":"Hearne Michael S","position":1,"cik":"0001759910","reported_name":"Hearne Michael S","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Common Stock","published_at":"2022-05-17T17:07:17.000Z","date":"2022-05-13","kind":"grant","acquired":true,"shares":188,"price":3.4085,"value":640.798,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"These shares were acquired on 5/13/2022 through the La Jolla Pharmaceutical Company 2018 Employee Stock Purchase Plan in a transaction that was exempt under both Rule 16b-3(d) and Rule 16b-3(c)."}],"balance_after":9525,"source":{"system":"sec-edgar","filing":"0001209191-22-029751","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/920465/000120919122029751/doc4.xml","form_type":"4"}},{"id":2285108,"issuer":{"id":124310,"kind":"organization","name":"LA JOLLA PHARMACEUTICAL CO","symbol":"LJPC"},"owners":[{"id":45594,"kind":"person","name":"Hearne Michael S","position":1,"cik":"0001759910","reported_name":"Hearne Michael S","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Employee Stock Option (Right to Buy)","published_at":"2022-05-03T17:00:27.000Z","date":"2022-04-29","kind":"grant","acquired":true,"shares":185,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"The stock options vest and become exercisable with respect to 25% of the underlying shares on the one-year anniversary of the grant date and then vest and become exercisable ratably on a monthly basis over the next three years."}],"balance_after":185,"derivative":{"exercise_price":4.08,"expiration_date":"2032-04-29","underlying":"Common Stock","underlying_shares":185},"source":{"system":"sec-edgar","filing":"0001209191-22-026783","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/920465/000120919122026783/doc4.xml","form_type":"4"}},{"id":2285107,"issuer":{"id":124310,"kind":"organization","name":"LA JOLLA PHARMACEUTICAL CO","symbol":"LJPC"},"owners":[{"id":45594,"kind":"person","name":"Hearne Michael S","position":1,"cik":"0001759910","reported_name":"Hearne Michael S","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Common Stock","published_at":"2022-05-03T17:00:27.000Z","date":"2022-04-29","kind":"grant","acquired":true,"shares":185,"price":3.468,"value":641.58,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"These shares were acquired on 4/29/2022 through the La Jolla Pharmaceutical Company 2018 Employee Stock Purchase Plan in a transaction that was exempt under both Rule 16b-3(d) and Rule 16b-3(c)."}],"balance_after":9337,"source":{"system":"sec-edgar","filing":"0001209191-22-026783","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/920465/000120919122026783/doc4.xml","form_type":"4"}},{"id":2295955,"issuer":{"id":124310,"kind":"organization","name":"LA JOLLA PHARMACEUTICAL CO","symbol":"LJPC"},"owners":[{"id":45594,"kind":"person","name":"Hearne Michael S","position":1,"cik":"0001759910","reported_name":"Hearne Michael S","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Employee Stock Option (Right to Buy)","published_at":"2022-04-18T18:31:10.000Z","date":"2022-04-14","kind":"grant","acquired":true,"shares":173,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"The stock options vest and become exercisable with respect to 25% of the underlying shares on the one-year anniversary of the grant date and then vest and become exercisable ratably on a monthly basis over the next three years."}],"balance_after":173,"derivative":{"exercise_price":4.37,"expiration_date":"2032-04-14","underlying":"Common Stock","underlying_shares":173},"source":{"system":"sec-edgar","filing":"0001209191-22-024634","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/920465/000120919122024634/doc4.xml","form_type":"4"}},{"id":2295954,"issuer":{"id":124310,"kind":"organization","name":"LA JOLLA PHARMACEUTICAL CO","symbol":"LJPC"},"owners":[{"id":45594,"kind":"person","name":"Hearne Michael S","position":1,"cik":"0001759910","reported_name":"Hearne Michael S","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Common Stock","published_at":"2022-04-18T18:31:10.000Z","date":"2022-04-14","kind":"grant","acquired":true,"shares":173,"price":3.7145,"value":642.6085,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"These shares were acquired on 4/14/2022 through the La Jolla Pharmaceutical Company 2018 Employee Stock Purchase Plan in a transaction that was exempt under both Rule 16b-3(d) and Rule 16b-3(c)."}],"balance_after":9152,"source":{"system":"sec-edgar","filing":"0001209191-22-024634","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/920465/000120919122024634/doc4.xml","form_type":"4"}},{"id":2309553,"issuer":{"id":124310,"kind":"organization","name":"LA JOLLA PHARMACEUTICAL CO","symbol":"LJPC"},"owners":[{"id":45594,"kind":"person","name":"Hearne Michael S","position":1,"cik":"0001759910","reported_name":"Hearne Michael S","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Employee Stock Option (Right to Buy)","published_at":"2022-04-04T17:38:20.000Z","date":"2022-03-31","kind":"grant","acquired":true,"shares":177,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"The stock options vest and become exercisable with respect to 25% of the underlying shares on the one-year anniversary of the grant date and then vest and become exercisable ratably on a monthly basis over the next three years."}],"balance_after":177,"derivative":{"exercise_price":4.27,"expiration_date":"2032-03-31","underlying":"Common Stock","underlying_shares":177},"source":{"system":"sec-edgar","filing":"0001209191-22-022587","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/920465/000120919122022587/doc4.xml","form_type":"4"}},{"id":2309552,"issuer":{"id":124310,"kind":"organization","name":"LA JOLLA PHARMACEUTICAL CO","symbol":"LJPC"},"owners":[{"id":45594,"kind":"person","name":"Hearne Michael S","position":1,"cik":"0001759910","reported_name":"Hearne Michael S","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Common Stock","published_at":"2022-04-04T17:38:20.000Z","date":"2022-03-31","kind":"grant","acquired":true,"shares":177,"price":3.6295,"value":642.4215,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"These shares were acquired on 3/31/2022 through the La Jolla Pharmaceutical Company 2018 Employee Stock Purchase Plan in a transaction that was exempt under both Rule 16b-3(d) and Rule 16b-3(c)."}],"balance_after":8979,"source":{"system":"sec-edgar","filing":"0001209191-22-022587","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/920465/000120919122022587/doc4.xml","form_type":"4"}},{"id":2328963,"issuer":{"id":124310,"kind":"organization","name":"LA JOLLA PHARMACEUTICAL CO","symbol":"LJPC"},"owners":[{"id":45594,"kind":"person","name":"Hearne Michael S","position":1,"cik":"0001759910","reported_name":"Hearne Michael S","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Employee Stock Option (Right to Buy)","published_at":"2022-03-17T21:04:26.000Z","date":"2022-03-15","kind":"grant","acquired":true,"shares":190,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"The stock options vest and become exercisable with respect to 25% of the underlying shares on the one-year anniversary of the grant date and then vest and become exercisable ratably on a monthly basis over the next three years."}],"balance_after":190,"derivative":{"exercise_price":3.96,"expiration_date":"2032-03-15","underlying":"Common Stock","underlying_shares":190},"source":{"system":"sec-edgar","filing":"0001209191-22-019899","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/920465/000120919122019899/doc4.xml","form_type":"4"}},{"id":2328962,"issuer":{"id":124310,"kind":"organization","name":"LA JOLLA PHARMACEUTICAL CO","symbol":"LJPC"},"owners":[{"id":45594,"kind":"person","name":"Hearne Michael S","position":1,"cik":"0001759910","reported_name":"Hearne Michael S","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Common Stock","published_at":"2022-03-17T21:04:26.000Z","date":"2022-03-15","kind":"grant","acquired":true,"shares":190,"price":3.366,"value":639.54,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"These shares were acquired on 3/15/2022 through the La Jolla Pharmaceutical Company 2018 Employee Stock Purchase Plan in a transaction that was exempt under both Rule 16b-3(d) and Rule 16b-3(c)."}],"balance_after":8802,"source":{"system":"sec-edgar","filing":"0001209191-22-019899","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/920465/000120919122019899/doc4.xml","form_type":"4"}},{"id":2362522,"issuer":{"id":124310,"kind":"organization","name":"LA JOLLA PHARMACEUTICAL CO","symbol":"LJPC"},"owners":[{"id":45594,"kind":"person","name":"Hearne Michael S","position":1,"cik":"0001759910","reported_name":"Hearne Michael S","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Employee Stock Option (Right to Buy)","published_at":"2022-03-02T17:07:21.000Z","date":"2022-02-28","kind":"grant","acquired":true,"shares":185,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"The stock options vest and become exercisable with respect to 25% of the underlying shares on the one-year anniversary of the grant date and then vest and become exercisable ratably on a monthly basis over the next three years."}],"balance_after":185,"derivative":{"exercise_price":4.09,"expiration_date":"2032-02-28","underlying":"Common Stock","underlying_shares":185},"source":{"system":"sec-edgar","filing":"0001209191-22-014875","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/920465/000120919122014875/doc4.xml","form_type":"4"}},{"id":2362521,"issuer":{"id":124310,"kind":"organization","name":"LA JOLLA PHARMACEUTICAL CO","symbol":"LJPC"},"owners":[{"id":45594,"kind":"person","name":"Hearne Michael S","position":1,"cik":"0001759910","reported_name":"Hearne Michael S","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Common Stock","published_at":"2022-03-02T17:07:21.000Z","date":"2022-02-28","kind":"grant","acquired":true,"shares":185,"price":3.4765,"value":643.1525,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"These shares were acquired on 2/28/2022 through the La Jolla Pharmaceutical Company 2018 Employee Stock Purchase Plan in a transaction that was exempt under both Rule 16b-3(d) and Rule 16b-3(c)."}],"balance_after":8612,"source":{"system":"sec-edgar","filing":"0001209191-22-014875","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/920465/000120919122014875/doc4.xml","form_type":"4"}},{"id":2389682,"issuer":{"id":124310,"kind":"organization","name":"LA JOLLA PHARMACEUTICAL CO","symbol":"LJPC"},"owners":[{"id":45594,"kind":"person","name":"Hearne Michael S","position":1,"cik":"0001759910","reported_name":"Hearne Michael S","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Employee Stock Option (Right to Buy)","published_at":"2022-02-17T17:05:22.000Z","date":"2022-02-15","kind":"grant","acquired":true,"shares":169,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"The stock options vest and become exercisable with respect to 25% of the underlying shares on the one-year anniversary of the grant date and then vest and become exercisable ratably on a monthly basis over the next three years."}],"balance_after":169,"derivative":{"exercise_price":4.46,"expiration_date":"2032-02-15","underlying":"Common Stock","underlying_shares":169},"source":{"system":"sec-edgar","filing":"0001209191-22-010852","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/920465/000120919122010852/doc4.xml","form_type":"4"}},{"id":2389681,"issuer":{"id":124310,"kind":"organization","name":"LA JOLLA PHARMACEUTICAL CO","symbol":"LJPC"},"owners":[{"id":45594,"kind":"person","name":"Hearne Michael S","position":1,"cik":"0001759910","reported_name":"Hearne Michael S","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Common Stock","published_at":"2022-02-17T17:05:22.000Z","date":"2022-02-15","kind":"grant","acquired":true,"shares":169,"price":3.791,"value":640.679,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"These shares were acquired on 2/15/2022 through the La Jolla Pharmaceutical Company 2018 Employee Stock Purchase Plan in a transaction that was exempt under both Rule 16b-3(d) and Rule 16b-3(c)."}],"balance_after":8427,"source":{"system":"sec-edgar","filing":"0001209191-22-010852","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/920465/000120919122010852/doc4.xml","form_type":"4"}},{"id":2417534,"issuer":{"id":124310,"kind":"organization","name":"LA JOLLA PHARMACEUTICAL CO","symbol":"LJPC"},"owners":[{"id":45594,"kind":"person","name":"Hearne Michael S","position":1,"cik":"0001759910","reported_name":"Hearne Michael S","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Employee Stock Option (Right to Buy)","published_at":"2022-02-02T19:19:58.000Z","date":"2022-01-31","kind":"grant","acquired":true,"shares":1675,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"The stock options vest and become exercisable with respect to 25% of the underlying shares on the one-year anniversary of the grant date and then vest and become exercisable ratably on a monthly basis over the next three years."}],"balance_after":1675,"derivative":{"exercise_price":4.63,"expiration_date":"2032-01-31","underlying":"Common Stock","underlying_shares":1675},"source":{"system":"sec-edgar","filing":"0001209191-22-006559","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/920465/000120919122006559/doc4.xml","form_type":"4"}},{"id":2417533,"issuer":{"id":124310,"kind":"organization","name":"LA JOLLA PHARMACEUTICAL CO","symbol":"LJPC"},"owners":[{"id":45594,"kind":"person","name":"Hearne Michael S","position":1,"cik":"0001759910","reported_name":"Hearne Michael S","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Common Stock","published_at":"2022-02-02T19:19:58.000Z","date":"2022-01-31","kind":"grant","acquired":true,"shares":1675,"price":3.9355,"value":6591.9625,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"These shares were acquired on 1/31/2022 through the La Jolla Pharmaceutical Company 2018 Employee Stock Purchase Plan in a transaction that was exempt under both Rule 16b-3(d) and Rule 16b-3(c)."}],"balance_after":8258,"source":{"system":"sec-edgar","filing":"0001209191-22-006559","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/920465/000120919122006559/doc4.xml","form_type":"4"}},{"id":2432917,"issuer":{"id":124310,"kind":"organization","name":"LA JOLLA PHARMACEUTICAL CO","symbol":"LJPC"},"owners":[{"id":45594,"kind":"person","name":"Hearne Michael S","position":1,"cik":"0001759910","reported_name":"Hearne Michael S","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Employee Stock Option (Right to Buy)","published_at":"2022-01-19T20:26:20.000Z","date":"2022-01-14","kind":"grant","acquired":true,"shares":148,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"The stock options vest and become exercisable with respect to 25% of the underlying shares on the one-year anniversary of the grant date and then vest and become exercisable ratably on a monthly basis over the next three years."}],"balance_after":148,"derivative":{"exercise_price":4.92,"expiration_date":"2032-01-14","underlying":"Common Stock","underlying_shares":148},"source":{"system":"sec-edgar","filing":"0001209191-22-003889","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/920465/000120919122003889/doc4.xml","form_type":"4"}},{"id":2432916,"issuer":{"id":124310,"kind":"organization","name":"LA JOLLA PHARMACEUTICAL CO","symbol":"LJPC"},"owners":[{"id":45594,"kind":"person","name":"Hearne Michael S","position":1,"cik":"0001759910","reported_name":"Hearne Michael S","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Common Stock","published_at":"2022-01-19T20:26:20.000Z","date":"2022-01-14","kind":"grant","acquired":true,"shares":148,"price":4.182,"value":618.936,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"These shares were acquired on 1/14/2022 through the La Jolla Pharmaceutical Company 2018 Employee Stock Purchase Plan in a transaction that was exempt under both Rule 16b-3(d) and Rule 16b-3(c)."}],"balance_after":6583,"source":{"system":"sec-edgar","filing":"0001209191-22-003889","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/920465/000120919122003889/doc4.xml","form_type":"4"}},{"id":2435285,"issuer":{"id":124310,"kind":"organization","name":"LA JOLLA PHARMACEUTICAL CO","symbol":"LJPC"},"owners":[{"id":45594,"kind":"person","name":"Hearne Michael S","position":1,"cik":"0001759910","reported_name":"Hearne Michael S","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Employee Stock Option (Right to Buy)","published_at":"2022-01-14T18:27:23.000Z","date":"2022-01-12","kind":"grant","acquired":true,"shares":78552,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The stock option vests and becomes exercisable with respect to 25% of the underlying shares on the one-year anniversary of grant date and then vests and becomes exercisable ratably on a monthly basis over the next three years."}],"balance_after":78552,"derivative":{"exercise_price":4.81,"expiration_date":"2032-01-12","underlying":"Common Stock","underlying_shares":78552},"source":{"system":"sec-edgar","filing":"0001209191-22-003385","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/920465/000120919122003385/doc4.xml","form_type":"4"}},{"id":2451539,"issuer":{"id":124310,"kind":"organization","name":"LA JOLLA PHARMACEUTICAL CO","symbol":"LJPC"},"owners":[{"id":45594,"kind":"person","name":"Hearne Michael S","position":1,"cik":"0001759910","reported_name":"Hearne Michael S","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Employee Stock Option (Right to Buy)","published_at":"2022-01-04T17:05:20.000Z","date":"2021-12-30","kind":"grant","acquired":true,"shares":157,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"The stock options vest and become exercisable with respect to 25% of the underlying shares on the one-year anniversary of the grant date and then vest and become exercisable ratably on a monthly basis over the next three years."}],"balance_after":157,"derivative":{"exercise_price":4.61,"expiration_date":"2031-12-30","underlying":"Common Stock","underlying_shares":157},"source":{"system":"sec-edgar","filing":"0001209191-22-000956","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/920465/000120919122000956/doc4.xml","form_type":"4"}},{"id":2451538,"issuer":{"id":124310,"kind":"organization","name":"LA JOLLA PHARMACEUTICAL CO","symbol":"LJPC"},"owners":[{"id":45594,"kind":"person","name":"Hearne Michael S","position":1,"cik":"0001759910","reported_name":"Hearne Michael S","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Common Stock","published_at":"2022-01-04T17:05:20.000Z","date":"2021-12-30","kind":"grant","acquired":true,"shares":157,"price":3.9185,"value":615.2045,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"These shares were acquired on 12/30/2021 through the La Jolla Pharmaceutical Company 2018 Employee Stock Purchase Plan in a transaction that was exempt under both Rule 16b-3(d) and Rule 16b-3(c)."}],"balance_after":6435,"source":{"system":"sec-edgar","filing":"0001209191-22-000956","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/920465/000120919122000956/doc4.xml","form_type":"4"}},{"id":2468446,"issuer":{"id":124310,"kind":"organization","name":"LA JOLLA PHARMACEUTICAL CO","symbol":"LJPC"},"owners":[{"id":45594,"kind":"person","name":"Hearne Michael S","position":1,"cik":"0001759910","reported_name":"Hearne Michael S","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Employee Stock Option (Right to Buy)","published_at":"2021-12-17T17:58:52.000Z","date":"2021-12-15","kind":"grant","acquired":true,"shares":173,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"The stock options vest and become exercisable with respect to 25% of the underlying shares on the one-year anniversary of the grant date and then vest and become exercisable ratably on a monthly basis over the next three years."}],"balance_after":173,"derivative":{"exercise_price":4.21,"expiration_date":"2031-12-15","underlying":"Common Stock","underlying_shares":173},"source":{"system":"sec-edgar","filing":"0001209191-21-070378","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/920465/000120919121070378/doc4.xml","form_type":"4"}},{"id":2468445,"issuer":{"id":124310,"kind":"organization","name":"LA JOLLA PHARMACEUTICAL CO","symbol":"LJPC"},"owners":[{"id":45594,"kind":"person","name":"Hearne Michael S","position":1,"cik":"0001759910","reported_name":"Hearne Michael S","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Common Stock","published_at":"2021-12-17T17:58:52.000Z","date":"2021-12-15","kind":"grant","acquired":true,"shares":173,"price":3.5785,"value":619.0805,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"These shares were acquired on 12/15/2021 through the La Jolla Pharmaceutical Company 2018 Employee Stock Purchase Plan in a transaction that was exempt under both Rule 16b-3(d) and Rule 16b-3(c)."}],"balance_after":6278,"source":{"system":"sec-edgar","filing":"0001209191-21-070378","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/920465/000120919121070378/doc4.xml","form_type":"4"}},{"id":2489592,"issuer":{"id":124310,"kind":"organization","name":"LA JOLLA PHARMACEUTICAL CO","symbol":"LJPC"},"owners":[{"id":45594,"kind":"person","name":"Hearne Michael S","position":1,"cik":"0001759910","reported_name":"Hearne Michael S","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Employee Stock Option (Right to Buy)","published_at":"2021-12-02T17:05:10.000Z","date":"2021-11-30","kind":"grant","acquired":true,"shares":186,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"The stock options vest and become exercisable with respect to 25% of the underlying shares on the one-year anniversary of the grant date and then vest and become exercisable ratably on a monthly basis over the next three years."}],"balance_after":186,"derivative":{"exercise_price":3.9,"expiration_date":"2031-11-30","underlying":"Common Stock","underlying_shares":186},"source":{"system":"sec-edgar","filing":"0001209191-21-067643","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/920465/000120919121067643/doc4.xml","form_type":"4"}},{"id":2489591,"issuer":{"id":124310,"kind":"organization","name":"LA JOLLA PHARMACEUTICAL CO","symbol":"LJPC"},"owners":[{"id":45594,"kind":"person","name":"Hearne Michael S","position":1,"cik":"0001759910","reported_name":"Hearne Michael S","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Common Stock","published_at":"2021-12-02T17:05:10.000Z","date":"2021-11-30","kind":"grant","acquired":true,"shares":186,"price":3.315,"value":616.59,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"These shares were acquired on 11/30/2021 through the La Jolla Pharmaceutical Company 2018 Employee Stock Purchase Plan in a transaction that was exempt under both Rule 16b-3(d) and Rule 16b-3(c)."}],"balance_after":6105,"source":{"system":"sec-edgar","filing":"0001209191-21-067643","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/920465/000120919121067643/doc4.xml","form_type":"4"}},{"id":2491145,"issuer":{"id":124310,"kind":"organization","name":"LA JOLLA PHARMACEUTICAL CO","symbol":"LJPC"},"owners":[{"id":18814,"kind":"person","name":"TANG KEVIN","position":1,"cik":"0001178579","reported_name":"TANG KEVIN C","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":82742,"kind":"organization","name":"TANG CAPITAL PARTNERS LP","position":2,"cik":"0001191935","reported_name":"TANG CAPITAL PARTNERS LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":18815,"kind":"organization","name":"TANG CAPITAL MANAGEMENT LLC","position":3,"cik":"0001232621","reported_name":"TANG CAPITAL MANAGEMENT LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":45594,"kind":"person","name":"Hearne Michael S","position":4,"cik":"0001759910","reported_name":"Hearne Michael S","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Common Stock","published_at":"2021-12-01T19:07:25.000Z","date":"2021-12-01","kind":"sale","acquired":false,"shares":41290,"price":3.6644,"value":151303.076,"ownership":{"direct":false,"nature":"By LP"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F7","text":"The prices reported in Column 4 are weighted-average prices. These shares were sold in multiple transactions at prices ranging from $3.60 to $3.75"},{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F3","text":"The shares are beneficially owned by Tang Capital Partners, LP (\"TCP\"). Kevin Tang is the sole manager of Tang Capital Management, LLC (\"TCM\"), which is the general partner of TCP. Michael Hearne is the Chief Financial Officer of La Jolla Pharmaceutical Company, as well as Chief Financial Officer of TCM. Mr. Tang and Mr. Hearne each have a pecuniary interest in the shares beneficially held by TCP."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"The shares are beneficially owned by Tang Capital Partners, LP (\"TCP\"). Kevin Tang is the sole manager of Tang Capital Management, LLC (\"TCM\"), which is the general partner of TCP. Michael Hearne is the Chief Financial Officer of La Jolla Pharmaceutical Company, as well as Chief Financial Officer of TCM. Mr. Tang and Mr. Hearne each have a pecuniary interest in the shares beneficially held by TCP."}],"balance_after":9607934,"source":{"system":"sec-edgar","filing":"0001209191-21-067347","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/920465/000120919121067347/doc4.xml","form_type":"4"}},{"id":2491144,"issuer":{"id":124310,"kind":"organization","name":"LA JOLLA PHARMACEUTICAL CO","symbol":"LJPC"},"owners":[{"id":18814,"kind":"person","name":"TANG KEVIN","position":1,"cik":"0001178579","reported_name":"TANG KEVIN C","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":82742,"kind":"organization","name":"TANG CAPITAL PARTNERS LP","position":2,"cik":"0001191935","reported_name":"TANG CAPITAL PARTNERS LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":18815,"kind":"organization","name":"TANG CAPITAL MANAGEMENT LLC","position":3,"cik":"0001232621","reported_name":"TANG CAPITAL MANAGEMENT LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":45594,"kind":"person","name":"Hearne Michael S","position":4,"cik":"0001759910","reported_name":"Hearne Michael S","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Common Stock","published_at":"2021-12-01T19:07:25.000Z","date":"2021-12-01","kind":"sale","acquired":false,"shares":136255,"price":3.7586,"value":512128.043,"ownership":{"direct":false,"nature":"By LP"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F6","text":"The prices reported in Column 4 are weighted-average prices. These shares were sold in multiple transactions at prices ranging from $3.70 to $3.89."},{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F3","text":"The shares are beneficially owned by Tang Capital Partners, LP (\"TCP\"). Kevin Tang is the sole manager of Tang Capital Management, LLC (\"TCM\"), which is the general partner of TCP. Michael Hearne is the Chief Financial Officer of La Jolla Pharmaceutical Company, as well as Chief Financial Officer of TCM. Mr. Tang and Mr. Hearne each have a pecuniary interest in the shares beneficially held by TCP."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"The shares are beneficially owned by Tang Capital Partners, LP (\"TCP\"). Kevin Tang is the sole manager of Tang Capital Management, LLC (\"TCM\"), which is the general partner of TCP. Michael Hearne is the Chief Financial Officer of La Jolla Pharmaceutical Company, as well as Chief Financial Officer of TCM. Mr. Tang and Mr. Hearne each have a pecuniary interest in the shares beneficially held by TCP."}],"balance_after":9649224,"source":{"system":"sec-edgar","filing":"0001209191-21-067347","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/920465/000120919121067347/doc4.xml","form_type":"4"}},{"id":2491143,"issuer":{"id":124310,"kind":"organization","name":"LA JOLLA PHARMACEUTICAL CO","symbol":"LJPC"},"owners":[{"id":18814,"kind":"person","name":"TANG KEVIN","position":1,"cik":"0001178579","reported_name":"TANG KEVIN C","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":82742,"kind":"organization","name":"TANG CAPITAL PARTNERS LP","position":2,"cik":"0001191935","reported_name":"TANG CAPITAL PARTNERS LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":18815,"kind":"organization","name":"TANG CAPITAL MANAGEMENT LLC","position":3,"cik":"0001232621","reported_name":"TANG CAPITAL MANAGEMENT LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":45594,"kind":"person","name":"Hearne Michael S","position":4,"cik":"0001759910","reported_name":"Hearne Michael S","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Common Stock","published_at":"2021-12-01T19:07:25.000Z","date":"2021-11-30","kind":"sale","acquired":false,"shares":63745,"price":3.9461,"value":251544.1445,"ownership":{"direct":false,"nature":"By LP"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F5","text":"The prices reported in Column 4 are weighted-average prices. These shares were sold in multiple transactions at prices ranging from $3.90 to $4.051."},{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F3","text":"The shares are beneficially owned by Tang Capital Partners, LP (\"TCP\"). Kevin Tang is the sole manager of Tang Capital Management, LLC (\"TCM\"), which is the general partner of TCP. Michael Hearne is the Chief Financial Officer of La Jolla Pharmaceutical Company, as well as Chief Financial Officer of TCM. Mr. Tang and Mr. Hearne each have a pecuniary interest in the shares beneficially held by TCP."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"The shares are beneficially owned by Tang Capital Partners, LP (\"TCP\"). Kevin Tang is the sole manager of Tang Capital Management, LLC (\"TCM\"), which is the general partner of TCP. Michael Hearne is the Chief Financial Officer of La Jolla Pharmaceutical Company, as well as Chief Financial Officer of TCM. Mr. Tang and Mr. Hearne each have a pecuniary interest in the shares beneficially held by TCP."}],"balance_after":9785479,"source":{"system":"sec-edgar","filing":"0001209191-21-067347","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/920465/000120919121067347/doc4.xml","form_type":"4"}},{"id":2491142,"issuer":{"id":124310,"kind":"organization","name":"LA JOLLA PHARMACEUTICAL CO","symbol":"LJPC"},"owners":[{"id":18814,"kind":"person","name":"TANG KEVIN","position":1,"cik":"0001178579","reported_name":"TANG KEVIN C","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":82742,"kind":"organization","name":"TANG CAPITAL PARTNERS LP","position":2,"cik":"0001191935","reported_name":"TANG CAPITAL PARTNERS LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":18815,"kind":"organization","name":"TANG CAPITAL MANAGEMENT LLC","position":3,"cik":"0001232621","reported_name":"TANG CAPITAL MANAGEMENT LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":45594,"kind":"person","name":"Hearne Michael S","position":4,"cik":"0001759910","reported_name":"Hearne Michael S","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Common Stock","published_at":"2021-12-01T19:07:25.000Z","date":"2021-11-30","kind":"sale","acquired":false,"shares":6597,"price":3.9514,"value":26067.3858,"ownership":{"direct":false,"nature":"By LP"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F4","text":"The prices reported in Column 4 are weighted-average prices. These shares were sold in multiple transactions at prices ranging from $3.95 to $3.96."},{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F3","text":"The shares are beneficially owned by Tang Capital Partners, LP (\"TCP\"). Kevin Tang is the sole manager of Tang Capital Management, LLC (\"TCM\"), which is the general partner of TCP. Michael Hearne is the Chief Financial Officer of La Jolla Pharmaceutical Company, as well as Chief Financial Officer of TCM. Mr. Tang and Mr. Hearne each have a pecuniary interest in the shares beneficially held by TCP."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"The shares are beneficially owned by Tang Capital Partners, LP (\"TCP\"). Kevin Tang is the sole manager of Tang Capital Management, LLC (\"TCM\"), which is the general partner of TCP. Michael Hearne is the Chief Financial Officer of La Jolla Pharmaceutical Company, as well as Chief Financial Officer of TCM. Mr. Tang and Mr. Hearne each have a pecuniary interest in the shares beneficially held by TCP."}],"balance_after":9849224,"source":{"system":"sec-edgar","filing":"0001209191-21-067347","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/920465/000120919121067347/doc4.xml","form_type":"4"}},{"id":2491141,"issuer":{"id":124310,"kind":"organization","name":"LA JOLLA PHARMACEUTICAL CO","symbol":"LJPC"},"owners":[{"id":18814,"kind":"person","name":"TANG KEVIN","position":1,"cik":"0001178579","reported_name":"TANG KEVIN C","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":82742,"kind":"organization","name":"TANG CAPITAL PARTNERS LP","position":2,"cik":"0001191935","reported_name":"TANG CAPITAL PARTNERS LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":18815,"kind":"organization","name":"TANG CAPITAL MANAGEMENT LLC","position":3,"cik":"0001232621","reported_name":"TANG CAPITAL MANAGEMENT LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":45594,"kind":"person","name":"Hearne Michael S","position":4,"cik":"0001759910","reported_name":"Hearne Michael S","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Common Stock","published_at":"2021-12-01T19:07:25.000Z","date":"2021-11-29","kind":"sale","acquired":false,"shares":193403,"price":4.1008,"value":793107.0224,"ownership":{"direct":false,"nature":"By LP"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The Reporting Person has delivered to the Issuer the full amount of the disgorgeable profit arising the sale reported herein, in the amount of $4,380.25."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The prices reported in Column 4 are weighted-average prices. These shares were sold in multiple transactions at prices ranging from $3.90 to $4.74. The\nReporting Persons undertake to provide the Issuer, any security holder of the Issuer or the SEC Staff, upon request, full information regarding the number of shares sold at each price within the ranges set forth in footnotes 2 and 4 through 7 herein."},{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F3","text":"The shares are beneficially owned by Tang Capital Partners, LP (\"TCP\"). Kevin Tang is the sole manager of Tang Capital Management, LLC (\"TCM\"), which is the general partner of TCP. Michael Hearne is the Chief Financial Officer of La Jolla Pharmaceutical Company, as well as Chief Financial Officer of TCM. Mr. Tang and Mr. Hearne each have a pecuniary interest in the shares beneficially held by TCP."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"The shares are beneficially owned by Tang Capital Partners, LP (\"TCP\"). Kevin Tang is the sole manager of Tang Capital Management, LLC (\"TCM\"), which is the general partner of TCP. Michael Hearne is the Chief Financial Officer of La Jolla Pharmaceutical Company, as well as Chief Financial Officer of TCM. Mr. Tang and Mr. Hearne each have a pecuniary interest in the shares beneficially held by TCP."}],"balance_after":9855821,"source":{"system":"sec-edgar","filing":"0001209191-21-067347","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/920465/000120919121067347/doc4.xml","form_type":"4"}},{"id":2503305,"issuer":{"id":132524,"kind":"organization","name":"Odonate Therapeutics, Inc.","symbol":"ODT"},"owners":[{"id":18814,"kind":"person","name":"TANG KEVIN","position":1,"cik":"0001178579","reported_name":"TANG KEVIN C","relationship":{"director":true,"officer":true,"ten_percent_owner":true,"other":false,"officer_title":"Chief Executive Officer"}},{"id":82742,"kind":"organization","name":"TANG CAPITAL PARTNERS LP","position":2,"cik":"0001191935","reported_name":"TANG CAPITAL PARTNERS LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":18815,"kind":"organization","name":"TANG CAPITAL MANAGEMENT LLC","position":3,"cik":"0001232621","reported_name":"TANG CAPITAL MANAGEMENT LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":45594,"kind":"person","name":"Hearne Michael S","position":4,"cik":"0001759910","reported_name":"Hearne Michael S","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Common Stock","published_at":"2021-11-19T21:38:52.000Z","date":"2021-11-19","kind":"sale","acquired":false,"shares":365289,"price":1.9161,"value":699930.2529,"ownership":{"direct":false,"nature":"By LP"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F9","text":"The prices reported in Column 4 are weighted-average prices. These shares were sold in multiple transactions at prices ranging from $1.85 to $1.985."},{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F2","text":"The securities are beneficially owned by Tang Capital Partners, LP (\"TCP\"). Kevin Tang is the sole manager of Tang Capital Management,\nLLC (\"TCM\"), which is the general partner of TCP. The shares reported as beneficially owned by TCP include a total of 154,285 shares of\ncommon stock that are held of record by Odonate Holdings, LLC (\"Holdings\"). Holdings has granted a proxy to TCP giving TCP the sole authority\nto vote such shares. Michael Hearne is the Chief Financial Officer of Odonate Therapeutics, Inc., as well as Chief Financial Officer of TCM. Mr. Tang and Mr. Hearne each have a pecuniary interest in a portion of the shares beneficially held by TCP."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"The securities are beneficially owned by Tang Capital Partners, LP (\"TCP\"). Kevin Tang is the sole manager of Tang Capital Management,\nLLC (\"TCM\"), which is the general partner of TCP. The shares reported as beneficially owned by TCP include a total of 154,285 shares of\ncommon stock that are held of record by Odonate Holdings, LLC (\"Holdings\"). Holdings has granted a proxy to TCP giving TCP the sole authority\nto vote such shares. Michael Hearne is the Chief Financial Officer of Odonate Therapeutics, Inc., as well as Chief Financial Officer of TCM. Mr. Tang and Mr. Hearne each have a pecuniary interest in a portion of the shares beneficially held by TCP."}],"balance_after":12767435,"source":{"system":"sec-edgar","filing":"0001209191-21-065826","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":8,"url":"https://www.sec.gov/Archives/edgar/data/1178579/000120919121065826/doc4.xml","form_type":"4"}},{"id":2503304,"issuer":{"id":132524,"kind":"organization","name":"Odonate Therapeutics, Inc.","symbol":"ODT"},"owners":[{"id":18814,"kind":"person","name":"TANG KEVIN","position":1,"cik":"0001178579","reported_name":"TANG KEVIN C","relationship":{"director":true,"officer":true,"ten_percent_owner":true,"other":false,"officer_title":"Chief Executive Officer"}},{"id":82742,"kind":"organization","name":"TANG CAPITAL PARTNERS LP","position":2,"cik":"0001191935","reported_name":"TANG CAPITAL PARTNERS LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":18815,"kind":"organization","name":"TANG CAPITAL MANAGEMENT LLC","position":3,"cik":"0001232621","reported_name":"TANG CAPITAL MANAGEMENT LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":45594,"kind":"person","name":"Hearne Michael S","position":4,"cik":"0001759910","reported_name":"Hearne Michael S","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Common Stock","published_at":"2021-11-19T21:38:52.000Z","date":"2021-11-18","kind":"sale","acquired":false,"shares":381842,"price":1.8925,"value":722635.985,"ownership":{"direct":false,"nature":"By LP"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F8","text":"The prices reported in Column 4 are weighted-average prices. These shares were sold in multiple transactions at prices ranging from $1.85 to $2.001."},{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F2","text":"The securities are beneficially owned by Tang Capital Partners, LP (\"TCP\"). Kevin Tang is the sole manager of Tang Capital Management,\nLLC (\"TCM\"), which is the general partner of TCP. The shares reported as beneficially owned by TCP include a total of 154,285 shares of\ncommon stock that are held of record by Odonate Holdings, LLC (\"Holdings\"). Holdings has granted a proxy to TCP giving TCP the sole authority\nto vote such shares. Michael Hearne is the Chief Financial Officer of Odonate Therapeutics, Inc., as well as Chief Financial Officer of TCM. Mr. Tang and Mr. Hearne each have a pecuniary interest in a portion of the shares beneficially held by TCP."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"The securities are beneficially owned by Tang Capital Partners, LP (\"TCP\"). Kevin Tang is the sole manager of Tang Capital Management,\nLLC (\"TCM\"), which is the general partner of TCP. The shares reported as beneficially owned by TCP include a total of 154,285 shares of\ncommon stock that are held of record by Odonate Holdings, LLC (\"Holdings\"). Holdings has granted a proxy to TCP giving TCP the sole authority\nto vote such shares. Michael Hearne is the Chief Financial Officer of Odonate Therapeutics, Inc., as well as Chief Financial Officer of TCM. Mr. Tang and Mr. Hearne each have a pecuniary interest in a portion of the shares beneficially held by TCP."}],"balance_after":13132724,"source":{"system":"sec-edgar","filing":"0001209191-21-065826","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":7,"url":"https://www.sec.gov/Archives/edgar/data/1178579/000120919121065826/doc4.xml","form_type":"4"}},{"id":2503303,"issuer":{"id":132524,"kind":"organization","name":"Odonate Therapeutics, Inc.","symbol":"ODT"},"owners":[{"id":18814,"kind":"person","name":"TANG KEVIN","position":1,"cik":"0001178579","reported_name":"TANG KEVIN C","relationship":{"director":true,"officer":true,"ten_percent_owner":true,"other":false,"officer_title":"Chief Executive Officer"}},{"id":82742,"kind":"organization","name":"TANG CAPITAL PARTNERS LP","position":2,"cik":"0001191935","reported_name":"TANG CAPITAL PARTNERS LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":18815,"kind":"organization","name":"TANG CAPITAL MANAGEMENT LLC","position":3,"cik":"0001232621","reported_name":"TANG CAPITAL MANAGEMENT LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":45594,"kind":"person","name":"Hearne Michael S","position":4,"cik":"0001759910","reported_name":"Hearne Michael S","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Common Stock","published_at":"2021-11-19T21:38:52.000Z","date":"2021-11-18","kind":"sale","acquired":false,"shares":500000,"price":1.8812,"value":940600.0,"ownership":{"direct":false,"nature":"By LP"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F7","text":"The prices reported in Column 4 are weighted-average prices. These shares were sold in multiple transactions at prices ranging from $1.85 to $1.99."},{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F2","text":"The securities are beneficially owned by Tang Capital Partners, LP (\"TCP\"). Kevin Tang is the sole manager of Tang Capital Management,\nLLC (\"TCM\"), which is the general partner of TCP. The shares reported as beneficially owned by TCP include a total of 154,285 shares of\ncommon stock that are held of record by Odonate Holdings, LLC (\"Holdings\"). Holdings has granted a proxy to TCP giving TCP the sole authority\nto vote such shares. Michael Hearne is the Chief Financial Officer of Odonate Therapeutics, Inc., as well as Chief Financial Officer of TCM. Mr. Tang and Mr. Hearne each have a pecuniary interest in a portion of the shares beneficially held by TCP."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"The securities are beneficially owned by Tang Capital Partners, LP (\"TCP\"). Kevin Tang is the sole manager of Tang Capital Management,\nLLC (\"TCM\"), which is the general partner of TCP. The shares reported as beneficially owned by TCP include a total of 154,285 shares of\ncommon stock that are held of record by Odonate Holdings, LLC (\"Holdings\"). Holdings has granted a proxy to TCP giving TCP the sole authority\nto vote such shares. Michael Hearne is the Chief Financial Officer of Odonate Therapeutics, Inc., as well as Chief Financial Officer of TCM. Mr. Tang and Mr. Hearne each have a pecuniary interest in a portion of the shares beneficially held by TCP."}],"balance_after":13514566,"source":{"system":"sec-edgar","filing":"0001209191-21-065826","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/1178579/000120919121065826/doc4.xml","form_type":"4"}},{"id":2503302,"issuer":{"id":132524,"kind":"organization","name":"Odonate Therapeutics, Inc.","symbol":"ODT"},"owners":[{"id":18814,"kind":"person","name":"TANG KEVIN","position":1,"cik":"0001178579","reported_name":"TANG KEVIN C","relationship":{"director":true,"officer":true,"ten_percent_owner":true,"other":false,"officer_title":"Chief Executive Officer"}},{"id":82742,"kind":"organization","name":"TANG CAPITAL PARTNERS LP","position":2,"cik":"0001191935","reported_name":"TANG CAPITAL PARTNERS LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":18815,"kind":"organization","name":"TANG CAPITAL MANAGEMENT LLC","position":3,"cik":"0001232621","reported_name":"TANG CAPITAL MANAGEMENT LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":45594,"kind":"person","name":"Hearne Michael S","position":4,"cik":"0001759910","reported_name":"Hearne Michael S","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Common Stock","published_at":"2021-11-19T21:38:52.000Z","date":"2021-11-18","kind":"sale","acquired":false,"shares":212423,"price":1.9708,"value":418643.2484,"ownership":{"direct":false,"nature":"By LP"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F6","text":"The prices reported in Column 4 are weighted-average prices. These shares were sold in multiple transactions at prices ranging from $1.91 to $2.16."},{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F2","text":"The securities are beneficially owned by Tang Capital Partners, LP (\"TCP\"). Kevin Tang is the sole manager of Tang Capital Management,\nLLC (\"TCM\"), which is the general partner of TCP. The shares reported as beneficially owned by TCP include a total of 154,285 shares of\ncommon stock that are held of record by Odonate Holdings, LLC (\"Holdings\"). Holdings has granted a proxy to TCP giving TCP the sole authority\nto vote such shares. Michael Hearne is the Chief Financial Officer of Odonate Therapeutics, Inc., as well as Chief Financial Officer of TCM. Mr. Tang and Mr. Hearne each have a pecuniary interest in a portion of the shares beneficially held by TCP."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"The securities are beneficially owned by Tang Capital Partners, LP (\"TCP\"). Kevin Tang is the sole manager of Tang Capital Management,\nLLC (\"TCM\"), which is the general partner of TCP. The shares reported as beneficially owned by TCP include a total of 154,285 shares of\ncommon stock that are held of record by Odonate Holdings, LLC (\"Holdings\"). Holdings has granted a proxy to TCP giving TCP the sole authority\nto vote such shares. Michael Hearne is the Chief Financial Officer of Odonate Therapeutics, Inc., as well as Chief Financial Officer of TCM. Mr. Tang and Mr. Hearne each have a pecuniary interest in a portion of the shares beneficially held by TCP."}],"balance_after":14014566,"source":{"system":"sec-edgar","filing":"0001209191-21-065826","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1178579/000120919121065826/doc4.xml","form_type":"4"}},{"id":2503301,"issuer":{"id":132524,"kind":"organization","name":"Odonate Therapeutics, Inc.","symbol":"ODT"},"owners":[{"id":18814,"kind":"person","name":"TANG KEVIN","position":1,"cik":"0001178579","reported_name":"TANG KEVIN C","relationship":{"director":true,"officer":true,"ten_percent_owner":true,"other":false,"officer_title":"Chief Executive Officer"}},{"id":82742,"kind":"organization","name":"TANG CAPITAL PARTNERS LP","position":2,"cik":"0001191935","reported_name":"TANG CAPITAL PARTNERS LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":18815,"kind":"organization","name":"TANG CAPITAL MANAGEMENT LLC","position":3,"cik":"0001232621","reported_name":"TANG CAPITAL MANAGEMENT LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":45594,"kind":"person","name":"Hearne Michael S","position":4,"cik":"0001759910","reported_name":"Hearne Michael S","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Common Stock","published_at":"2021-11-19T21:38:52.000Z","date":"2021-11-17","kind":"sale","acquired":false,"shares":287577,"price":2.1985,"value":632238.0345,"ownership":{"direct":false,"nature":"By LP"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F5","text":"The prices reported in Column 4 are weighted-average prices. These shares were sold in multiple transactions at prices ranging from $2.10 to $2.33."},{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F2","text":"The securities are beneficially owned by Tang Capital Partners, LP (\"TCP\"). Kevin Tang is the sole manager of Tang Capital Management,\nLLC (\"TCM\"), which is the general partner of TCP. The shares reported as beneficially owned by TCP include a total of 154,285 shares of\ncommon stock that are held of record by Odonate Holdings, LLC (\"Holdings\"). Holdings has granted a proxy to TCP giving TCP the sole authority\nto vote such shares. Michael Hearne is the Chief Financial Officer of Odonate Therapeutics, Inc., as well as Chief Financial Officer of TCM. Mr. Tang and Mr. Hearne each have a pecuniary interest in a portion of the shares beneficially held by TCP."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"The securities are beneficially owned by Tang Capital Partners, LP (\"TCP\"). Kevin Tang is the sole manager of Tang Capital Management,\nLLC (\"TCM\"), which is the general partner of TCP. The shares reported as beneficially owned by TCP include a total of 154,285 shares of\ncommon stock that are held of record by Odonate Holdings, LLC (\"Holdings\"). Holdings has granted a proxy to TCP giving TCP the sole authority\nto vote such shares. Michael Hearne is the Chief Financial Officer of Odonate Therapeutics, Inc., as well as Chief Financial Officer of TCM. Mr. Tang and Mr. Hearne each have a pecuniary interest in a portion of the shares beneficially held by TCP."}],"balance_after":14226989,"source":{"system":"sec-edgar","filing":"0001209191-21-065826","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1178579/000120919121065826/doc4.xml","form_type":"4"}},{"id":2503300,"issuer":{"id":132524,"kind":"organization","name":"Odonate Therapeutics, Inc.","symbol":"ODT"},"owners":[{"id":18814,"kind":"person","name":"TANG KEVIN","position":1,"cik":"0001178579","reported_name":"TANG KEVIN C","relationship":{"director":true,"officer":true,"ten_percent_owner":true,"other":false,"officer_title":"Chief Executive Officer"}},{"id":82742,"kind":"organization","name":"TANG CAPITAL PARTNERS LP","position":2,"cik":"0001191935","reported_name":"TANG CAPITAL PARTNERS LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":18815,"kind":"organization","name":"TANG CAPITAL MANAGEMENT LLC","position":3,"cik":"0001232621","reported_name":"TANG CAPITAL MANAGEMENT LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":45594,"kind":"person","name":"Hearne Michael S","position":4,"cik":"0001759910","reported_name":"Hearne Michael S","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Common Stock","published_at":"2021-11-19T21:38:52.000Z","date":"2021-11-17","kind":"sale","acquired":false,"shares":500000,"price":2.0161,"value":1008050.0,"ownership":{"direct":false,"nature":"By LP"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F4","text":"The prices reported in Column 4 are weighted-average prices. These shares were sold in multiple transactions at prices ranging from $1.95 to $2.07."},{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F2","text":"The securities are beneficially owned by Tang Capital Partners, LP (\"TCP\"). Kevin Tang is the sole manager of Tang Capital Management,\nLLC (\"TCM\"), which is the general partner of TCP. The shares reported as beneficially owned by TCP include a total of 154,285 shares of\ncommon stock that are held of record by Odonate Holdings, LLC (\"Holdings\"). Holdings has granted a proxy to TCP giving TCP the sole authority\nto vote such shares. Michael Hearne is the Chief Financial Officer of Odonate Therapeutics, Inc., as well as Chief Financial Officer of TCM. Mr. Tang and Mr. Hearne each have a pecuniary interest in a portion of the shares beneficially held by TCP."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"The securities are beneficially owned by Tang Capital Partners, LP (\"TCP\"). Kevin Tang is the sole manager of Tang Capital Management,\nLLC (\"TCM\"), which is the general partner of TCP. The shares reported as beneficially owned by TCP include a total of 154,285 shares of\ncommon stock that are held of record by Odonate Holdings, LLC (\"Holdings\"). Holdings has granted a proxy to TCP giving TCP the sole authority\nto vote such shares. Michael Hearne is the Chief Financial Officer of Odonate Therapeutics, Inc., as well as Chief Financial Officer of TCM. Mr. Tang and Mr. Hearne each have a pecuniary interest in a portion of the shares beneficially held by TCP."}],"balance_after":14514566,"source":{"system":"sec-edgar","filing":"0001209191-21-065826","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1178579/000120919121065826/doc4.xml","form_type":"4"}},{"id":2503299,"issuer":{"id":132524,"kind":"organization","name":"Odonate Therapeutics, Inc.","symbol":"ODT"},"owners":[{"id":18814,"kind":"person","name":"TANG KEVIN","position":1,"cik":"0001178579","reported_name":"TANG KEVIN C","relationship":{"director":true,"officer":true,"ten_percent_owner":true,"other":false,"officer_title":"Chief Executive Officer"}},{"id":82742,"kind":"organization","name":"TANG CAPITAL PARTNERS LP","position":2,"cik":"0001191935","reported_name":"TANG CAPITAL PARTNERS LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":18815,"kind":"organization","name":"TANG CAPITAL MANAGEMENT LLC","position":3,"cik":"0001232621","reported_name":"TANG CAPITAL MANAGEMENT LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":45594,"kind":"person","name":"Hearne Michael S","position":4,"cik":"0001759910","reported_name":"Hearne Michael S","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Common Stock","published_at":"2021-11-19T21:38:52.000Z","date":"2021-11-17","kind":"sale","acquired":false,"shares":31151,"price":1.9941,"value":62118.2091,"ownership":{"direct":false,"nature":"By LP"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F3","text":"The prices reported in Column 4 are weighted-average prices. These shares were sold in multiple transactions at prices ranging from $1.99 to $2.005."},{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F2","text":"The securities are beneficially owned by Tang Capital Partners, LP (\"TCP\"). Kevin Tang is the sole manager of Tang Capital Management,\nLLC (\"TCM\"), which is the general partner of TCP. The shares reported as beneficially owned by TCP include a total of 154,285 shares of\ncommon stock that are held of record by Odonate Holdings, LLC (\"Holdings\"). Holdings has granted a proxy to TCP giving TCP the sole authority\nto vote such shares. Michael Hearne is the Chief Financial Officer of Odonate Therapeutics, Inc., as well as Chief Financial Officer of TCM. Mr. Tang and Mr. Hearne each have a pecuniary interest in a portion of the shares beneficially held by TCP."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"The securities are beneficially owned by Tang Capital Partners, LP (\"TCP\"). Kevin Tang is the sole manager of Tang Capital Management,\nLLC (\"TCM\"), which is the general partner of TCP. The shares reported as beneficially owned by TCP include a total of 154,285 shares of\ncommon stock that are held of record by Odonate Holdings, LLC (\"Holdings\"). Holdings has granted a proxy to TCP giving TCP the sole authority\nto vote such shares. Michael Hearne is the Chief Financial Officer of Odonate Therapeutics, Inc., as well as Chief Financial Officer of TCM. Mr. Tang and Mr. Hearne each have a pecuniary interest in a portion of the shares beneficially held by TCP."}],"balance_after":15014566,"source":{"system":"sec-edgar","filing":"0001209191-21-065826","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1178579/000120919121065826/doc4.xml","form_type":"4"}},{"id":2503298,"issuer":{"id":132524,"kind":"organization","name":"Odonate Therapeutics, Inc.","symbol":"ODT"},"owners":[{"id":18814,"kind":"person","name":"TANG KEVIN","position":1,"cik":"0001178579","reported_name":"TANG KEVIN C","relationship":{"director":true,"officer":true,"ten_percent_owner":true,"other":false,"officer_title":"Chief Executive Officer"}},{"id":82742,"kind":"organization","name":"TANG CAPITAL PARTNERS LP","position":2,"cik":"0001191935","reported_name":"TANG CAPITAL PARTNERS LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":18815,"kind":"organization","name":"TANG CAPITAL MANAGEMENT LLC","position":3,"cik":"0001232621","reported_name":"TANG CAPITAL MANAGEMENT LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":45594,"kind":"person","name":"Hearne Michael S","position":4,"cik":"0001759910","reported_name":"Hearne Michael S","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Common Stock","published_at":"2021-11-19T21:38:52.000Z","date":"2021-11-17","kind":"sale","acquired":false,"shares":468849,"price":2.6583,"value":1246341.2967,"ownership":{"direct":false,"nature":"By LP"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The prices reported in Column 4 are weighted-average prices. These shares were sold in multiple transactions at prices ranging from $2.01 to $3.01. The Reporting Persons undertake to provide the Issuer, any security holder of the Issuer or the SEC Staff, upon request, full information regarding the number of shares sold at each price within the ranges set forth in footnotes 1 and 3 through 9 herein."},{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F2","text":"The securities are beneficially owned by Tang Capital Partners, LP (\"TCP\"). Kevin Tang is the sole manager of Tang Capital Management,\nLLC (\"TCM\"), which is the general partner of TCP. The shares reported as beneficially owned by TCP include a total of 154,285 shares of\ncommon stock that are held of record by Odonate Holdings, LLC (\"Holdings\"). Holdings has granted a proxy to TCP giving TCP the sole authority\nto vote such shares. Michael Hearne is the Chief Financial Officer of Odonate Therapeutics, Inc., as well as Chief Financial Officer of TCM. Mr. Tang and Mr. Hearne each have a pecuniary interest in a portion of the shares beneficially held by TCP."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"The securities are beneficially owned by Tang Capital Partners, LP (\"TCP\"). Kevin Tang is the sole manager of Tang Capital Management,\nLLC (\"TCM\"), which is the general partner of TCP. The shares reported as beneficially owned by TCP include a total of 154,285 shares of\ncommon stock that are held of record by Odonate Holdings, LLC (\"Holdings\"). Holdings has granted a proxy to TCP giving TCP the sole authority\nto vote such shares. Michael Hearne is the Chief Financial Officer of Odonate Therapeutics, Inc., as well as Chief Financial Officer of TCM. Mr. Tang and Mr. Hearne each have a pecuniary interest in a portion of the shares beneficially held by TCP."}],"balance_after":15045717,"source":{"system":"sec-edgar","filing":"0001209191-21-065826","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1178579/000120919121065826/doc4.xml","form_type":"4"}},{"id":2508755,"issuer":{"id":124310,"kind":"organization","name":"LA JOLLA PHARMACEUTICAL CO","symbol":"LJPC"},"owners":[{"id":45594,"kind":"person","name":"Hearne Michael S","position":1,"cik":"0001759910","reported_name":"Hearne Michael S","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Employee Stock Option (Right to Buy)","published_at":"2021-11-17T17:05:16.000Z","date":"2021-11-15","kind":"grant","acquired":true,"shares":181,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"The stock options vest and become exercisable with respect to 25% of the underlying shares on the one-year anniversary of the grant date and then vest and become exercisable ratably on a monthly basis over the next three years."}],"balance_after":181,"derivative":{"exercise_price":4.01,"expiration_date":"2031-11-15","underlying":"Common Stock","underlying_shares":181},"source":{"system":"sec-edgar","filing":"0001209191-21-065155","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/920465/000120919121065155/doc4.xml","form_type":"4"}},{"id":2508754,"issuer":{"id":124310,"kind":"organization","name":"LA JOLLA PHARMACEUTICAL CO","symbol":"LJPC"},"owners":[{"id":45594,"kind":"person","name":"Hearne Michael S","position":1,"cik":"0001759910","reported_name":"Hearne Michael S","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Common Stock","published_at":"2021-11-17T17:05:16.000Z","date":"2021-11-15","kind":"grant","acquired":true,"shares":181,"price":3.4085,"value":616.9385,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"These shares were acquired on 11/15/2021 through the La Jolla Pharmaceutical Company 2018 Employee Stock Purchase Plan in a transaction that was exempt under both Rule 16b-3(d) and Rule 16b-3(c)."}],"balance_after":5919,"source":{"system":"sec-edgar","filing":"0001209191-21-065155","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/920465/000120919121065155/doc4.xml","form_type":"4"}},{"id":2529750,"issuer":{"id":124310,"kind":"organization","name":"LA JOLLA PHARMACEUTICAL CO","symbol":"LJPC"},"owners":[{"id":45594,"kind":"person","name":"Hearne Michael S","position":1,"cik":"0001759910","reported_name":"Hearne Michael S","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Employee Stock Option (Right to Buy)","published_at":"2021-11-02T17:05:46.000Z","date":"2021-10-29","kind":"grant","acquired":true,"shares":181,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"The stock options vest and become exercisable with respect to 25% of the underlying shares on the one-year anniversary of the grant date and then vest and become exercisable ratably on a monthly basis over the next three years."}],"balance_after":181,"derivative":{"exercise_price":4.02,"expiration_date":"2031-10-29","underlying":"Common Stock","underlying_shares":181},"source":{"system":"sec-edgar","filing":"0001209191-21-062451","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/920465/000120919121062451/doc4.xml","form_type":"4"}},{"id":2529749,"issuer":{"id":124310,"kind":"organization","name":"LA JOLLA PHARMACEUTICAL CO","symbol":"LJPC"},"owners":[{"id":45594,"kind":"person","name":"Hearne Michael S","position":1,"cik":"0001759910","reported_name":"Hearne Michael S","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Common Stock","published_at":"2021-11-02T17:05:46.000Z","date":"2021-10-29","kind":"grant","acquired":true,"shares":181,"price":3.417,"value":618.477,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"These shares were acquired on 10/29/2021 through the La Jolla Pharmaceutical Company 2018 Employee Stock Purchase Plan in a transaction that was exempt under both Rule 16b-3(d) and Rule 16b-3(c)."}],"balance_after":5738,"source":{"system":"sec-edgar","filing":"0001209191-21-062451","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/920465/000120919121062451/doc4.xml","form_type":"4"}},{"id":2539872,"issuer":{"id":124310,"kind":"organization","name":"LA JOLLA PHARMACEUTICAL CO","symbol":"LJPC"},"owners":[{"id":45594,"kind":"person","name":"Hearne Michael S","position":1,"cik":"0001759910","reported_name":"Hearne Michael S","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Employee Stock Option (Right to Buy)","published_at":"2021-10-19T17:05:12.000Z","date":"2021-10-15","kind":"grant","acquired":true,"shares":183,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"The stock options vest and become exercisable with respect to 25% of the underlying shares on the one-year anniversary of the grant date and then vest and become exercisable ratably on a monthly basis over the next three years."}],"balance_after":183,"derivative":{"exercise_price":3.96,"expiration_date":"2031-10-15","underlying":"Common Stock","underlying_shares":183},"source":{"system":"sec-edgar","filing":"0001209191-21-060947","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/920465/000120919121060947/doc4.xml","form_type":"4"}},{"id":2539871,"issuer":{"id":124310,"kind":"organization","name":"LA JOLLA PHARMACEUTICAL CO","symbol":"LJPC"},"owners":[{"id":45594,"kind":"person","name":"Hearne Michael S","position":1,"cik":"0001759910","reported_name":"Hearne Michael S","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Common Stock","published_at":"2021-10-19T17:05:12.000Z","date":"2021-10-15","kind":"grant","acquired":true,"shares":183,"price":3.366,"value":615.978,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"These shares were acquired on 10/15/2021 through the La Jolla Pharmaceutical Company 2018 Employee Stock Purchase Plan in a transaction that was exempt under both Rule 16b-3(d) and Rule 16b-3(c)."}],"balance_after":5557,"source":{"system":"sec-edgar","filing":"0001209191-21-060947","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/920465/000120919121060947/doc4.xml","form_type":"4"}},{"id":2552973,"issuer":{"id":124310,"kind":"organization","name":"LA JOLLA PHARMACEUTICAL CO","symbol":"LJPC"},"owners":[{"id":45594,"kind":"person","name":"Hearne Michael S","position":1,"cik":"0001759910","reported_name":"Hearne Michael S","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Employee Stock Option (Right to Buy)","published_at":"2021-10-04T17:05:12.000Z","date":"2021-09-30","kind":"grant","acquired":true,"shares":182,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"The stock options vest and become exercisable with respect to 25% of the underlying shares on the one-year anniversary of the grant date and then vest and become exercisable ratably on a monthly basis over the next three years."}],"balance_after":182,"derivative":{"exercise_price":3.99,"expiration_date":"2031-09-30","underlying":"Common Stock","underlying_shares":182},"source":{"system":"sec-edgar","filing":"0001209191-21-059054","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/920465/000120919121059054/doc4.xml","form_type":"4"}},{"id":2552972,"issuer":{"id":124310,"kind":"organization","name":"LA JOLLA PHARMACEUTICAL CO","symbol":"LJPC"},"owners":[{"id":45594,"kind":"person","name":"Hearne Michael S","position":1,"cik":"0001759910","reported_name":"Hearne Michael S","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Common Stock","published_at":"2021-10-04T17:05:12.000Z","date":"2021-09-30","kind":"grant","acquired":true,"shares":182,"price":3.3915,"value":617.253,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"These shares were acquired on 9/30/2021 through the La Jolla Pharmaceutical Company 2018 Employee Stock Purchase Plan in a transaction that was exempt under both Rule 16b-3(d) and Rule 16b-3(c)."}],"balance_after":5374,"source":{"system":"sec-edgar","filing":"0001209191-21-059054","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/920465/000120919121059054/doc4.xml","form_type":"4"}},{"id":2566672,"issuer":{"id":124310,"kind":"organization","name":"LA JOLLA PHARMACEUTICAL CO","symbol":"LJPC"},"owners":[{"id":45594,"kind":"person","name":"Hearne Michael S","position":1,"cik":"0001759910","reported_name":"Hearne Michael S","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Employee Stock Option (Right to Buy)","published_at":"2021-09-17T17:05:10.000Z","date":"2021-09-15","kind":"grant","acquired":true,"shares":546,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"The stock options vest and become exercisable with respect to 25% of the underlying shares on the one-year anniversary of the grant date and then vest and become exercisable ratably on a monthly basis over the next three years."}],"balance_after":546,"derivative":{"exercise_price":3.99,"expiration_date":"2031-09-15","underlying":"Common Stock","underlying_shares":546},"source":{"system":"sec-edgar","filing":"0001209191-21-056669","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/920465/000120919121056669/doc4.xml","form_type":"4"}},{"id":2566671,"issuer":{"id":124310,"kind":"organization","name":"LA JOLLA PHARMACEUTICAL CO","symbol":"LJPC"},"owners":[{"id":45594,"kind":"person","name":"Hearne Michael S","position":1,"cik":"0001759910","reported_name":"Hearne Michael S","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Common Stock","published_at":"2021-09-17T17:05:10.000Z","date":"2021-09-15","kind":"grant","acquired":true,"shares":546,"price":3.3915,"value":1851.759,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"These shares were acquired on 9/15/2021 through the La Jolla Pharmaceutical Company 2018 Employee Stock Purchase Plan in a transaction that was exempt under both Rule 16b-3(d) and Rule 16b-3(c)."}],"balance_after":5192,"source":{"system":"sec-edgar","filing":"0001209191-21-056669","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/920465/000120919121056669/doc4.xml","form_type":"4"}},{"id":2618708,"issuer":{"id":124310,"kind":"organization","name":"LA JOLLA PHARMACEUTICAL CO","symbol":"LJPC"},"owners":[{"id":45594,"kind":"person","name":"Hearne Michael S","position":1,"cik":"0001759910","reported_name":"Hearne Michael S","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Employee Stock Option (Right to Buy)","published_at":"2021-08-03T17:05:27.000Z","date":"2021-07-30","kind":"grant","acquired":true,"shares":201,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"The stock options vest and become exercisable with respect to 25% of the underlying shares on the one-year anniversary of the grant date and then vest and become exercisable ratably on a monthly basis over the next three years."}],"balance_after":201,"derivative":{"exercise_price":3.61,"expiration_date":"2031-07-30","underlying":"Common Stock","underlying_shares":201},"source":{"system":"sec-edgar","filing":"0001209191-21-049386","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/920465/000120919121049386/doc4.xml","form_type":"4"}}],"next_cursor":"2021-08-03T17:05:27.000000Z,2618708"}